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PRELIMINARY REMARK 
 
 
While conventional chemotherapy and radiation therapy have improved the 
survival of many cancer patients, there are still major disadvantages associated 
with these treatments such as high toxicity and drug-resistance. The possibility to 
manipulate the immune system to recognize and kill tumor cells is very attractive 
despite numerous obstacles remaining to be overcome, such as tolerance and 
tumor escape. In particular, the ability of the immune system to seek out and 
destroy disseminated micro-metastases in a specific way makes immunotherapy 
an attractive alternative or complement to conventional therapies. Nevertheless 
today other unconventional technologies have reached many progresses, in 
particular the analysis and monitoring of single cell-to-cell interactions and the 
capability of individually controlling single cells have become of interest in different 
areas of life sciences, ranging from immunotherapy and cancer research to rare 
cell identification and isolation. These new technologies in combination with 
progresses reached in anti-tumor vaccines could be useful to identify, understand 
and improve immune T cell responses against tumor antigen and the sensitization 
of tumors to T cell effector mechanisms for a more efficient immunotherapy.  
In particular, this thesis focuses on two tumor immunotherapy issues:  
1) design, realization and validation of innovative Lab-on-a-chip devices for 
immune system study, that allow single tumor cell and effector cells interaction, 
detection and isolation;  
2) identification of molecular mechanisms that prevent Burkitt‟s lymphoma 
recognition by T cells and study of their potential correction by specific treatments. 
The main goal of this study remains indeed the evaluation of integrated strategies 
for immunotherapy development enhancing for malignancies treatment.
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1 INTRODUCTION 
 
A Lab-on-a-chip (LOC) is a device that integrates one or several laboratory 
functions on a single chip of only millimeters to a few square centimeters in size. 
LOCs deal with the handling of extremely small fluid volumes down to less than 
pico liters. These devices are a subset of MicroElectroMechanical systems 
devices (MEMS) and often indicated by "Micro Total Analysis Systems" (µTAS) as 
well. In particular often LOC integrates microfluidics and electronics on the same 
platform. Microfluidics is a broader term that describes also mechanical flow 
control devices like pumps and valves or sensors like flowmeters and viscometers. 
However, strictly regarded "Lab-on-a-Chip" indicates generally the scaling of 
single or multiple lab processes down to chip-format, whereas "µTAS" is dedicated 
to the integration of the total sequence of lab processes to perform chemical 
analysis. The term "Lab-on-a-Chip" was introduced later on when it turned out that 
µTAS technologies were more widely applicable than only for analysis purposes. 
Although the application of LOCs is still novel and modest, a growing interest of 
companies and applied research groups is observed in different fields such as 
analysis (e.g. chemical analysis, environmental monitoring and medical 
diagnostics) but also in synthetic chemistry (e.g. rapid screening and 
microreactors for pharmaceutics). 
Besides further application developments, research in LOC systems is expected to 
extend towards downscaling of fluid handling structures as well, by using 
nanotechnology. Sub-micrometre and nano-sized channels, single cell detection 
and analysis, and nano-sensors, might become feasible, allowing new ways of 
interaction with biological species and molecules. The development of Lab-on-a-
chip devices for biomedical applications, including manipulation of single cells, is 
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an exciting new research field requiring strict collaboration between electronic 
engineers and biologists1-10. In the past few years, printed circuit board (PCB) 
technology, that can be used for Lab-on-a-chip devices producing, has reached a 
resolution of tens of micrometers, which is enough for many microfluidics 
applications11-14. The main limitation of this approach in biomedical applications 
remains constituent materials biocompatibility. Recently the range of materials for 
PCB technologies has been extended. Most of them have already been developed 
for flex circuits and have rapidly become an industrial standard. Cost-effective 
technologies have also been proposed by introducing additional preparatory 
steps15-16 or by testing corrosion-resistant materials (like aluminum) in standard 
PCB processes17. The use of these „„board technologies‟‟ is particularly relevant to 
the development of microtiter plates with sensoring and actuating features that 
allow fast, parallel manipulation and analysis of biological samples18-20. The 
adaptation of standard PCB processes, which ensure low production costs and 
large-scale development, may here boost progress in the design of many 
disposable applications. Lab-on-a-chip technology may soon become an important 
part of efforts to improve global health particularly through the development of 
point-of-care testing devices21. Despite the first LOC analysis system was 
developed in 1975 by S.C. Terry, Stanford University (it was a gas 
chromatograph), only at the end of the 1980s, and beginning of the 1990s, the 
LOC research started to seriously grow as a consequence of few research groups 
in Europe developing micropumps, flowsensors and concepts for integrated fluid 
treatments for analysis systems. A big boost in research and commercial interest 
came in the mid 1990‟s, when µTAS technologies turned out to provide interesting 
tooling for genomics applications, like capillary electrophoresis and DNA 
microarrays. 
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1.1 BIOSENSOR DESIGN AND TEST 
 
The idea of this project is to implement a microwell array using printed circuit 
board (PCB) technologies for the construction of the biosensor. Each microwell 
integrates actuation and sensing features by electrodes realized as structured 
conductor lines. The envisioned structure that is used for determining the cell-cell 
interaction by means of impedance change maintains the cells in equilibrium and 
traps them through dielectrophoresis forces (DEP). Figure 1 shows the sensor 
principle, but for the final device additional features will be added to the structure. 
Cells medium solution will flow from the bottom side into the microwells. 
Furthermore, a hydrophobic coating on PCB top will ease cell positioning into the 
microwells. Ultimately, the platform developed within the project, as shown in 
Figure 2, consists of an orderly matrix of up to thousands of microwells where 
living cells can be deposited and where microfluidics and electronics are 
integrated in a high-density circuit board.  
 
 
 
 
 
 
 
 
 
 
Figure 1. Biosensor principle, schematic cross section. This biosensor represents a novel concept 
of active microwells based on cylindrical wells able to vertically trap and control single particles by 
means of negative dielectrophoresis. The device is fabricated by drilling through holes on a solid 
substrate with metals layers, forming three annular electrodes within the well. A channel under the 
device provides a fluid flow filling the microwell by capillarity and cells or particles are delivered 
from the top by a microdispenser. 
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 The microwells are monitored by an external microscope, the electronics allow to 
control the biosensor electrodes, necessary to DEP forces induction, and to 
perform impedance measurements. The key point of this technology is that each 
microwell can force contact between individual cells, and detect consequences of 
these interactions. 
 
 
 
 
 
 
 
 
 
Figure 2. Example of matrix with up to thousands of microwells and a small assembled biosensor 
prototype with microfluidics and electronics integrated.  
 
 
1.1.1 Biosensor architecture 
 
Each microwell contains, as previously mentioned and as shown detail in Figure 
3D, three annular electrodes at the top, middle and bottom levels (TOP, MID and 
BOT electrodes); by applying them a sinusoidal signals at frequencies ranging 
from 100 kHz to 1.5MHz and amplitudes between 2V and 7V the microwell 
levitates the cells keeping them in the center of the structure. All possible 
configurations are obtained by applying the same sinusoidal signal on two 
electrodes and a counter-phase signal to the third one (Figure 3). The trap 
configuration is achieved by phase-shifting the MID electrode, thus creating an 
almost spherical cage at the level of the MID electrode and in the horizontal center 
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of the microwell. To guarantee this shape, the distance between TOP/MID and 
MID/BOT electrodes must be equal to the microwell diameter. Figure 3B shows a 
contour plot of the mean square electric field for a 2D structure representing a 
vertical cross section along one of the diameters of the hole. The reference 
particle for these simulations is a polystyrene bead. As it can be noticed in Figure 
3B, the trap mode also creates a semi-spherical cage on the top side of the 
microwell, thus preventing a particle dispensed from the top from entering the well. 
A different electrode polarization scheme is then used to create a load 
configuration by applying the counter-phase signal on BOT electrode (Figure 3A), 
thus creating an electric field minimum, in the region above MID electrode.   
                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 2D contour plot of mean square electric field on the vertical plane of a microwell. Load 
configuration (A) trap configuration (B) and eject configuration (C) are obtained by applying a 180° 
phase-shifted signal on Bottom (BOT), middle (MID) and TOP electrodes respectively and a 0° 
phase-shifted signal on the two remaining electrodes. (D) 3D views of the microwell; each 
microwell consists of a hole drilled on a flexible PCB substrate containing three annular electrodes 
(Top, Middle, Bottom). 
TOP
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D
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Finally, the eject configuration (Figure 3C) opens the cage from the bottom, 
allowing particles to be removed from the microwell. When implementing microwell 
arrays, independent addressing of single microwells is possible by changing the 
phases of the applied signals. An important consideration for cells controllability is 
related to the electrodes thickness, with particular reference to the middle 
electrode. As shown in Figure 3B, the region close to middle electrode has two 
electric fields maxima corresponding to the electrode edges, while in the middle 
region the electric field becomes null. As a consequence, the effect of the middle 
electrode to repel a particle towards the central region in negative 
dielectrophoresis (nDEP) conditions is reduced for particles with a small size 
compared to the electrode thickness. These particles, in fact, will find a region 
corresponding to the level at the center of the middle electrode where the 
horizontal DEP force becomes null or small. 
 
1.1.1.1 Fluid carrier 
 
Regarding the biosensor microfluidic, to provide a fluid flow to fill microwells and 
change the supernatant, a fluid carrier was created by structuring polycarbonate 
sheets and sealing them with silicone gaskets (Figure 4A). The carrier includes a 
chamber with height of 2mm, a volume of 4ml and a fluid inlet and outlet on two 
sides, providing fluids to microwells. Spring-loaded connectors were integrated to 
provide the signals to microwells (Figure 4B).  
 
 
 
 
 
A B
Figure 4. (A) Cross section of packaged system including the 
microwell array and the fluid carrier. (B) Photograph of a prototype 
of the microwell array mounted on a fluid carrier.
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1.1.1.2 Electrical interface 
 
In order to send electrical signals to the biosensor, a PCB board (named “PCB 
Host”) was realized (Figure 5A). The board is equipped with different connectors 
arrays and when the fluid carrier is positioned on the board the electrical contact 
are allowed (Figure 5B). In particular electrical signals for electrode polarization 
were generated by a multifunction synthesizer (Hewlett-Packard 8904A, Palo Alto, 
CA). The two sinusoidal signals have a frequency of 600 kHz, an amplitude 
between 0.2V and 0.7V, a programmable phase shift and were amplified by 10 
times on a custom circuit, thus providing a final amplitude between 2V and 7V. 
 
 
 
 
 
 
 
 
Figure 5. (A) Picture of “PCB Host” board, a red arrow indicates where fluid carrier will be 
positioned on the board (B) Picture of fluid carrier assembled on the “PCB Host” board. 
 
 
1.1.2 System architecture 
 
At the end, the biosensor considered in this thesis, is a fully automated system 
that integrates optical observation of microwells, alignment of target microwells 
beneath the microdispenser, automated motion, microfluidic handling and 
image/video capturing. Optical observation from the top of the microwell was 
performed by a fluorescence microscope (Nikon Eclipse 80i, Tokyo, Japan) 
A B
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equipped with a Nikon DXM1200 digital camera. Precise positioning within the 
micron-range of the biosensor under the microscope or under the microdispenser 
was made with an XYZ motorized microscope stage (Märzhäuser Wetzlar, 
Steindorf-Wetzlar, Germany). A fluid flow in the channel beneath the microwells 
was provided by a KDS-210 syringe pump (KD Scientific, Holliston, MA). All 
system parts were controlled by a set of modules implemented in LabView 
software (National Instruments, Austin, TX) to achieve complete automation of 
experimental procedures. The complete system architecture and its electrical and 
fluidic interfaces were specifically designed to maintain an easy way to 
disassemble the package, to remove the biosensor when necessary, replacing it 
with a new one and to perform the required cleaning procedures. A complete 
system scheme is reported in Figure 6, while Figure 7 shows its corresponding 3D 
view. 
 
 
 
 
 
 
 
 
 
 
 
  
                 Figure 6. System diagram. 
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1.2 CELL DELIVERY AND RECOVERY IN MICROWELLS 
 
Equipments and procedures for depositing cells into biosensor microwells, as well 
as for recovering specific cells from selected microwells, were also developed 
inside this project. In particular to identify the best and most suitable dispensing 
technique three different dispenser system were investigated:  
1.2.1) CellJet microdispenser. developed at Biochips Laboratory in CEA; 
1.2.2) a commercial piezoelectric jetting device; 
1.2.3) cell handling with a machined ceramic micropipette.  
The instrumentation for cell handling includes some mechanical supporting 
structures, such as, motorized stages, pressure control, optical devices, software, 
and development of operational loading methods (Figure 8).  
 
 
 
 
 
 
Figure 8. Integrated modules for cells dispensing and recovery towards microwells. 
 
 
 
Figure 7. 3D view of the system. 
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1.2.1 CellJet microdispenser 
 
In CellJet microdispenser, the cells are introduced into a microfluidic chip, 
transported and lined up along a microchannel, and detected by microelectrodes. 
For achieving cell dispense, some ~1 µL droplets are generated by a miniaturized 
solenoid valve so that the cells are brought out through the orifice of the 
microchannels. The cell-containing droplets are finally collected and absorbed by 
the microwell of the biosensor placed underneath (Figure 9). Deposited cells were 
proved to enter and pass through the microwells within few minutes. A software 
program for the cell microdispenser was developed, it automatically drives the 
CellJet microdispenser. Moreover, electrical profiles of cells flowing through the 
microfluidic chips were investigated to   parameterize cell dispense. 
 
 
 
 
 
 
 
 
 
1.2.2 Commercial piezoelectric jetting device 
 
In second analysis a commercial piezoelectric dispenser was also employed for 
cells depositing. As the diameter of human cells is about 20 µm, a dispenser with 
an orifice of 60 µm was chosen. The formed droplet has generally a diameter 
slightly larger than the orifice diameter, e.g. 65 µm in diameter which results in an 
Microdispenser 
Jet 
 
 
Figure 9. Spot dispensed onto a microwell by the CellJet microdispenser. The jet is narrow and 
very straight, allowing the spot to be located in the near vicinity of the microwell. The spot is 
absorbed by the microwell within seconds or minutes according to the fluidic resistance of the 
underneath microwell. 
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individual ejected volume of ~140 pL. A droplet generation requiring no pressure 
controller was implemented, and drivers using LabView software were 
programmed for controlling the electronic triggering of droplet jetting. Two modes 
of dispense were developed: a „stop-on-spot‟ mode where the biosensor is moved 
and stopped under the microdispenser for dispense; and a „in-fly ejection‟ mode 
where dispense is very rapid so that the ejected droplets can reach the 
underneath microwell while the biosensor is still moving at a constant velocity. 
Heterogeneity of the number of deposited cells were generally observed, which is 
likely due to sedimentation of cells upstream of the dispenser orifice. A classical 
limit dilution strategy, in which a low concentration of cells is introduced so that the 
total volume of cells statistically contains one single cell, was successfully 
investigated to resolve this heterogeneity.  
 
1.2.3 Cell handling with a machined micropipette 
 
Finally, a micropipette was machined from a capillary made in alumina (Al2O3) and 
toughened by zirconia (ZrO2), as shown in Figure 10. This material is very 
resistant to mechanical shocks and thus is tolerant to abrupt contacts with the 
microwell walls. Moreover, the micropipette extremity was micromachined for 
providing inner and outer diameters of 56 µm and 150 µm respectively. As a 
result, the pipette can handle T, B lymphocytes  and NK cells of ~8 µm in 
diameter, and tumor cells of epithelial origin and melanomas of ~16 µm in 
diameter, as well as penetrate into the conical entrance of the microwell (300-400 
µm in diameter) and collect the upper fraction of the microwell liquid. The 
microwell is supplied with liquid from the bottom fluidic chamber, and thus a 
prolonged aspiration of liquid by the micropipette is possible by continuous 
replacement of liquid during pipetting. Eventually, the meniscus height in the 
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microwell can be increased beyond the microwell border by controlling the 
pressure inside the fluidic chamber. Meniscus upward movements can form a 
droplet above the microwell which facilitates the contact between the pipette and 
the liquid and this aids the aspiration process. The ultrathin micropipette can be 
used both for depositing cells and for aspirating cells from microwells. By reversing 
the flow direction in the micropipette, the volume of liquid previously aspirated by 
the pipette can then be deposited into another microwell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ceramic
micropipette
Microwell 
with a 
going-out
meniscus
Figure 10. Handling of cell-containing liquid with a micromachined ceramic micropipette. The 
micropipette inner channel can be seen by transparency. A meniscus is formed above the 
microwell by enhancing pressure inside the fluidic biosensor chamber. 
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1.3 BIOSENSOR TECHNOLOGY AND MANUFACTURING 
 
A key point in this innovative device is the fabrication technology of the microwell 
array. Several technologies for microfluidic device fabrication and packaging have 
been proposed to integrate sensing capabilities and electrical interfaces into a 
single device. All these approaches require complex steps or expensive facilities, 
and mostly are useful for prototyping only. In opposition to existing technologies, 
the biosensor developed within this project needs to be low cost and disposable to 
be applicable for the intended purpose. Due to these requirements, standard 
printed circuit board (PCB) manufacturing processes were selected as base 
technology. In addition to be a low cost mass production tool, it allows the 
realization of fine structures and vias with feature widths below 100 µm. Drawback 
of this technology is the default use, as conductive substrate, of non-biocompatible 
materials as e.g. copper (Cu). Therefore, the first task was to identify a list of 
materials which could be processed with standard PCB technologies as 
substitutes of non-biocompatible materials. As a consequence with the hypothetic 
use of new materials and new material combinations also processes as 
lamination, conductor line structuring, microwell drilling, via formation and via 
metallization need to be developed or at least adapted. Additionally surface 
modifications have to be developed for the sensor manufacturing. The bottom side 
of the microwell sensor should have a hydrophilic surface for a bubble free wetting 
and flow of medium solution for the cells. On the other hand the top side of the 
sensor should have a hydrophobic surface for easier cell positioning into the 
microwell.  
 
 
 
INTRODUCTION                                                                                                                         Part I              
 16 
1.3.1 Materials selection 
 
In standard PCB manufacturing process typically Resin Coated Copper (RCC) and 
glass fiber filled epoxy films are used. These materials are not applicable for the 
microwell array realization due to copper incompatibility and the poor 
processability of fiber filled epoxies by laser structuring. Standard copper 
technology in combination with biocompatible metallization on top does not work 
due to the proposed manufacturing technology of the device (smearing of Cu 
particles during via drilling is contaminating also dielectric surfaces) and the 
metallization growth of an additional layer. Thus, no safe biocompatible device 
could be achieved using such a process combination. Therefore, new dielectric 
materials have to be evaluated in combination with biocompatible metal layers. As 
possible metals for conductive layer formation palladium, aluminum and gold were 
taken into account. Pyralux (Py), a B-staged modified acrylic adhesive, in 
combination with Polyimide, printable epoxies and epoxy films with aramid fibers 
have been discussed as dielectric layers. For the realization of the final Lab-on-
Substrate device also a hydrophobic / hydrophilic surface modification is needed, 
therefore, different coatings and modifications have to be evaluated. 
 
1.3.2 Lab-On-Substrate manufacturing process flow 
 
The starting process for PCB production, that will constitute biosensor heart/ 
physical support, is the lamination of the inner Aluminum–Pyralux–Polyimide layer. 
In sequential steps aluminum (Al) structuring is done by wet chemical etching 
followed by lamination of the next dielectric and metal layer. Final layer on top and 
bottom side is a Polyimide (PI) passivation. Microwells, through vias and blind vias 
are realized by laser drilling. The last process step would be the electroless metal 
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deposition for via metallization. Briefly, the general process sequence for Lab-On-
Substrate manufacturing with standard  technologies is shown in Figure 11. 
               
Figure 11. PCB manufacturing process flow. 
 
1.3.2.1 Lamination 
 
A Lauffer vacuum laminating press was used for all lamination processes 
described. This press allows the lamination under vacuum with defined 
parameters as pressure, temperature and time. The lamination process starts with 
a drying step at 50 °C under vacuum without pressure. The following lamination 
steps under force, heating and vacuum are used to achieve homogeneous layer 
thicknesses and good adhesion between the different layers. In particular Figure 
14 shows a cross section of a final laminated Al-Py-PI stack. 
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1.3.2.2 Microwell and via formation 
 
Once obtaining laminated Al-Py-PI stack it is necessary to create via and 
microwell inside the support for the final device ideation (Figure 12A). In particular 
for this purpose an UV laser system is used and the drilling process is milling the 
material through the laser beam. A 60 µm via in a Al-Py-PI stack of 210 µm overall 
thickness is shown in Figure 12B as an example. Due to the different material 
properties of Pyralux and the PI layer, the resulting via diameter of these materials 
is often different. Vias in Pyralux are larger, possibly due to a combination of 
higher ablation rate and larger thermal shrinkage with this material. Another 
important and crucial aspect of this process is the protection of the substrate 
surface, since the material removed during the laser drilling process can be re-
deposited and consequently contaminate the substrate surface.  
 
 
 
 
 
 
 
 
Figure 12. (A) Schematic cross section of device where microwell, different material layer and vias 
are shown (B) Picture of 60 µm via in Aluminum/Pyralux/Polyimide stack (Al/Py/PI). 
 
 
1.3.2.3 Via metallization 
 
An electroless Ni/Au process has been used to realize electrical connections 
between inner aluminum layers and solder able pads on top of the device. The 
basic process chain is a sequential treatment of the Al with different chemicals, 
A B
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which are needed to apply the desired pretreatment to the pads, followed by the 
electroless Ni and immersion Au deposition. 
 
1.3.2.4 Funnel  
 
To get cell spotting into the microwells easier, a funnel has been projected above 
each microwell, therefore on top of the final metal layer two thick polyimide layers 
will be laminated. The polyimide will act as passivation on the metal structures and 
as a base for funnels. Funnels are mechanically drilled before the microwells are 
drilled by laser. An example of a microwell with funnel structure is shown in Figure 
13. 
 
 
 
 
 
 
 
Figure 13. (A) Picture of funnel realized by mechanical drilling in the final Polyimide top layer; (B) 
Schematic microwell cross section where funnel is realized, different material layer assembled in 
final device are indicated in different colours. 
 
1.3.3 Hydrophobic / hydrophilic surface modifications 
 
Different hydrophobic/hydrophilic coatings on device have been investigated, for 
example, to ease cell positioning into the microwells or to ease flow inside 
biosensor microchannel. For these purposes, all materials used for device 
realization were characterized and classified according to their surface energy; in 
particular, contact angle measurement of different candidate materials were 
determined with test liquids bromonaphthalene (nonpolar), glycerol (slightly polar) 
Polyimide
4
Semipermeable membrane
PCB
A B
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and water (highly polar). It was found that the surfaces of both Polyimide and 
Aluminum must be treated to allow a designing of a hydrophilic/hydrophobic 
microfluidic network required for a successful operation of sensor devices. Other 
different surface modifications were considered e.g. fluoralkyl polymer, 
hydrocarbon polymer, octadecane thiol and SF6-plasma to increase 
hydrophobicity; and organic acids, O2-plasma and several polar silanes to 
increase hydrophilicity. 
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2 MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 Tested materials for biosensor manufacturing 
 
The materials under-test (Table 1) were embedded in standard multiwell plates for 
cell culture (Costar-Corning, USA) in which the biological experiments for 
biocompatibility were carried out. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  Table 1. Complete list and abbreviation of tested materials. 
Group Name Abbreviation 
M
e
ta
ls
 
Copper Cu 
Aluminum Al 
Palladium Pd 
Gold over Nickel Au over Ni 
Gold over Palladium Au over Pd 
   
D
ie
le
c
tr
ic
s
-a
d
h
e
s
iv
e
s
 
Polyimide PI 
Pyralux uncured Py uncured 
Pyralux cured Py cured 
Poly(dimethylsiloxane)  PDMS 
Polyurethane foil before lamination PF before lam 
Polyurethane foil after lamination PF after lam 
Polyurethane Powder PP 
Epoxy cured Epoxy cured 
Die Attach Film  DAF  
Aramid fiber cured Aramid fiber cured 
Aramid fiber uncured Aramid fiber uncured 
Tesa 4983 Tesa 4983 
Tesa 4985 Tesa 4985 
CMC 15581 CMC 15581 
   
S
u
rf
a
c
e
 t
re
a
tm
e
n
ts
 
Copper + Octadecanethiol Cu + ODT 
Palladium + Octadecanethiol Pd + ODT 
Gold over Nickel + Octadecanethiol Au over Ni + ODT 
Gold over Palladium + Octadecanethiol Au over Pd + ODT 
Certonal FC-732 Certonal FC-732 
Certonal FC-732 Tempered Certonal FC-732T 
Chemlease 41-90 Chemlease 
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The materials, mostly foil, were cut by laser machining in round samples of 5.7 
mm diameter for 96-well plates and 15 mm for 24-well plates. Blue film was used 
to cover the sample during the cutting preventing its surface contamination due to 
the melting materials produced by the laser process. The sample has been 
embedded in the well with a droplet of PDMS. It was dispensed in each well by an 
air pressured dispenser (EFD, USA) with a 0,020‟ tip (internal diameter; EFD 
Precision Tips, USA) applying a pressure of 1.5 bar for 2.3 s for a 96 well plates 
and 13.8 s for a 24 well plates. The dispensing parameters were defined by tuning 
dispensing time, fixed pressure and tip diameter. The covering of the sample 
edges was optically measured by a Wild H3Z microscope (Heerbrugg, 
Switzerland) equipped with a MFK II measuring system (Kappa, Germany) at 
different dispensing time for a 96-well. PDMS was partially dried for 5 minutes at 
45°C after the dispensing. The round samples were deposited by a vacuum tip 
(EFD, USA) applying a light pressure. The protocol including dispensing, heating 
and sample deposition was repeat for each row of the multiwell plate. Finally 
PDMS was fully cured at 45°C for 24 h.  
Aluminum (18 μm thickness, Al), Copper (136 μm thickness, Cu), Polyimide (100 
μm thickness) were bought in foils and tested without any further process. In 
particular in this study materials will be referred as uncured (the material as 
delivered), b-stage (intermediate stage of the curing process) and cured (after 
complete processing). 
In order to understand the possible effect of a non-complete curing of internal 
layers during lamination process, Pyralux LF0300 adhesive (DuPont, USA) and 
aramid fiber filled epoxy F161 (HEXCEL, California) were tested both as uncured 
and cured materials (Pyralux uncured or cured and aramid fiber uncured or cured). 
Similarly, Polyurethane films (TPU-4201, Epurex Films, Bayer MaterialScience, 
Germany) were tested either before and after the lamination process (PF before 
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lam and PF after lam), while a second type of Polyurethane (94AU925, Merkel 
Freudenberg Fluidtechnic, Hamburg, Germany) provided as powder (PP) was 
tested after lamination. 
Aramid fiber filled epoxy was laminated following the curing cycle reported in its 
datasheet (Hexel, California).  
Patternable Epoxy (SEMICOAT513E, Shin-Etsu Chemical Co. LTD., Japan) 
requires up to 150°C to be cured [60min, 100°C + 90 min, 150°C] (Epoxy cured). 
This temperature is not compatible with the multiwell plate made with Polystyrene, 
which glass transition temperature is 95°C. To overcome this limitation a film of 
epoxy, 100µm-thick, has been patterned on a support covered with cured 
Doubling silicone for dental copy (SUPERIUM Dubliersilikon, Weber Dental - 
Germany), cured, peeled out as a foil and cut by laser. The hydrophobicity of the 
Doubling silicone avoids the sticking of the epoxy film. 
The Die Attach Film (DAF) is a polymer film (thickness 120 mm) consisting of a 
thermosetting and UV curable resin. This commercially available film could also be 
used for large-area lamination of different layers, as is needed in the case of a 
multilayer PCB.  
Poly(dimethylsiloxane) (PDMS, Sylgard 184, DowCorning) was prepared mixing 
the two components of Sylgard 184 with a ratio of 1:10 for 5 minutes and 
degassed for 30 minutes at 0.1 bar (4 min were required to reach 0.1 bar), 
prepared according to previous study22, and cured in the well at 45°C overnight. 
Palladium (Pd) and Gold (Au) have been chemically deposited on copper 
substrates by electroless process. For Pd deposition, first Nickel (Ni) was 
deposited as adhesion layer (15 min, 90°C) followed by Pd activation (1 min, 
55°C) and Pd deposition (30 min, 60°C). For Au deposition on Ni (Au over Ni), Ni 
was deposited as adhesion layer (15 min, 90°C) followed by Pd activation (1 min, 
55°C) and Au deposition (30 min, 50°C). For Au deposition on Pd (Au over Pd), Ni 
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was deposited as adhesion layer (15 min, 90°C) followed by Pd activation (1 min, 
55°C), Pd deposition (30 min, 60°C) and Au deposition (30 min, 50°C). The Cu 
substrates were cleaned in HCl 0.5% for 30 sec before the deposition, rinsing with 
DI-water and drying with nitrogen. 
The acrylic adhesive transfer films Tesa 4985 and 4983 (Tesa tape, USA), with a 
thermal stability up to 200°C, and CMC 15581 (CMC technical tapes, Germany), 
with a thermal stability up to 130°C, have been prepared in multiwell plates. The 
tapes, protected on both sides by cover papers, have been cut in samples by 
laser. All the tapes are transparent and provide a permanent adhesion. The 
transfer tapes were stuck in the well and PDMS was manually dispensed to cover 
their edges and cured as for the other multiwell plates. 
Certonal FC-732 was deposited filling the well for half of its volume for 5 min, 
rinsing with water and drying with a nitrogen flux at RT. Certonal was also 
deposited on an aluminum foil and tempered for 20 min at 150°C on a hotplate 
(Certonal FC-732T), after which it was cut by laser. A thin layer of Chemlease 41-
90 (Chemlease) has been applied on an aluminum foil, tempered for 20 min at 
150°C on hotplate and cut in samples. 
The Au, Pd and Cu surfaces have been functionalized with 1-octadecanethiol 
(ODT) (Sigma-Aldrich) making it hydrophobic. Ethanol was deoxygenated with 
bubbling nitrogen for 1 h before using it as a solvent for thiols, but not purified 
further23 . The metal substrates, embedded in multiwell, have been cleaned with 
isopropanol for 2 h, rinsing with DI-water and ethanol before the thiol monolayer 
deposition (24 h at RT). ODT 1 mM has been prepared in ethanol. Any significant 
variation in the contact angle was recorded using piranha solution24 or plasma 
etching23 for the cleaning of the substrates. After the deposition, the samples were 
rinsed with ethanol and dried with a jet of high purity nitrogen. 
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Since all the surface treatments (Certonal, Chemlease and ODT) produce an 
hydrophobic behavior of the treated surface, the presence of these coatings was 
verified by measuring contact angle of the processed surfaces25. All materials 
were UV-light sterilized before testing. 
 
2.1.2 Cell lines and culture conditions 
 
Lymphoblastoid cell lines (LCL) have been obtained after infection of human B-
lymphocytes with B95.8 strain of Epstein-Barr Virus (EBV)26. LCL and the human 
erythroleukemia  K562 cells27 were maintained in RPMI 1640 medium (Sigma-
Aldrich, Milwaukee, Wisc., USA) at 37°C in a humidified 5% CO2 atmosphere, 
supplemented with 10% fetal bovine serum (FBS; CELBIO, Milano, Italy), 100 
units/ml penicillin and 100 g/ml streptomycin (Sigma-Aldrich, St.Louis, MO, 
USA). IB3-1 were cultured in LHC-8 (Gibco; Invitrogen, San Diego, CA) 
supplemented with 5% FBS. The other cell lines employed in this work such as 
221 and 221-G1 lymphoblastoid cells, NKL and YTS natural killer-like cell line 
were provided by Regina Elena Cancer Institute, Rome. 
 
 
2.1.3 Compounds used to induce erythroid differentiation in K562  
 
Mithramycin (Sigma-Aldrich, St.Louis, MO, USA), cytosine arabinoside (AraC) 
(Sigma-Aldrich, St.Louis, MO, USA), and a C(5) modified uracil derivate30 (referred 
as AA55) kindly provided by Prof. R. Corradini (Department of Organic and 
Industrial Chemistry, University of Parma).  
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2.2 METHODS 
 
 
2.2.1 Analysis of in vitro cell growth 
 
For studying the effects on in vitro cell growth, with continuous incubation or after 
pulse incubation (60 minutes) with the materials, cells were seeded at the initial 
cell concentration of 30,000 cells/ml (K562 cells) or 50,000 cells/ml (LCL and IB3-
1 cells), cultured in RPMI supplemented with 10% FBS (or LHC-8 supplemented 
with 5% FBS for IB3-1) and the cell number/ml was determined using a model ZBI 
Coulter Counter (Coulter Electronics, Hialeah, FL, USA) after different days of cell 
culture. 
 
 
2.2.2 Erythroid differentiation of K562 cells 
 
The experimental protocols for analysis of the effects of the biomaterials on the 
erythroid differentiation were the following: (a) K562 cells were cultured to within 
biomaterial-treated 24-well plates for different days and treated with 25 nM 
mithramycin a powerful inducer of erythroid differentiation28 (continuous exposure); 
(b) K562 cells were exposed to the different biomaterials for 1 hour, then washed, 
sub-cultured in standard medium conditions and treated with 25 nM mithramycin 
for the following days (short exposure).  The proportion of benzidine-positive cells 
was determined after 5 and 6 days of cell culture using a solution containing 0.2% 
benzidine in 5 M glacial acetic acid (10% H2O2)
29. 
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2.2.3 CTL-mediated LCL lysis: chromium release assay 
 
Monocyte-depleted PBLs from HLA-A2 positive blood donor were plated at 
3,5x106 cells per well in 24-well plates in RPMI 1640 containing 10% fetal bovine 
serum (FBS Hyclone; CELBIO, Milano, Italy) and stimulated with EBV nuclear 
antigen 3 (EBNA-3) SVR peptide (10 M). Cultures were restimulated after 7 and 
14 days, and the medium was supplemented from day 8 with 10 U/ml rIL-2 
(Chiron). On days 14 and 21, T cell cultures were tested for CTL activity using 
cytotoxicity assay. SVR-specific CTL cultures efficiently lysed SVR-pulsed human 
leukocyte antigen A2 (HLA-A2) positive LCLs, but did not lyse SVR-pulsed HLA-
A2 negative LCLs (data not shown). Cytotoxic activity was tested by a standard 5h 
51Cr-release assay31. Briefly, target cells were labeled with 0.1 µCi/106 cells of 
Na2
51CrO4 for 90 minutes at 37°C and pulsed for 45 minutes with 10
-5 M of peptide 
at 37°C. Cells were then washed and used as targets at different effector : target 
(E:T) ratios. Percentage specific lysis was calculated as 100 x (cpm sample - cpm 
medium)/ (cpm Triton X-100 - cpm medium), where cpm is counts per minute.  
 
2.2.4 Cytokine profiles 
 
Cytokines in tissue culture supernatants released from IB3-1 under analysis, were 
measured by Bio-Plex cytokine assay (Bio-Rad Laboratories, Hercules, CA)32,33 as 
described by the manufacturer. The Bio-Plex cytokine assay is designed for the 
multiplexed quantitative measurement of multiple cytokines in a single well using 
as little as 50 µl of sample. In our experiments, we used the premixed multiplex 
beads of the Bio-Plex human cytokine 11-Plex Panel, which included eleven 
cytokines (IL-1alpha, IL-2ralpha, IL-3, IL-12, CTACK, GRO-alpha, ICAM-1, LIF, M-
CSF, SDF-1alpha, TRAIL). Briefly, 50 μl of cytokine standards or samples 
(supernatants from treated cells) were incubated with 50 μl of anti-cytokine 
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conjugated beads in 96-well filter plates for 30 min at RT with shaking. Plates were 
then washed by vacuum filtration three times with 100 μl of Bio-Plex wash buffer, 
25 μl of diluted detection antibody were added, and plates were incubated for 30 
min at room temperature with shaking. After three filter washes, 50 μl of 
streptavidin-phycoerythrin was added, and the plates were incubated for 10 min at 
room temperature with shaking. Finally, plates were washed by vacuum filtration 
three times, beads were suspended in Bio-Plex assay buffer, and samples were 
analyzed on a Bio-Rad 96-well plate reader using the Bio-Plex Suspension Array 
System and Bio-Plex Manager software (Bio-Rad Laboratories, Hercules, CA). 
 
2.2.5 RNA isolation  
 
Total RNA was phenol–chloroform-extracted from cytoplasm of treated and 
untreated K562 cells28. All solutions were made in diethylpyrocarbonate (DEPC)-
treated water. The extracted RNA was precipitated in two volumes of absolute 
ethanol and stored at −80 °C, washed once with cold 75% ethanol, dried and 
dissolved in DEPC-treated water before use. 
 
2.2.6 Real-time quantitative RT-PCR 
 
Quantitative real-time PCR assay of α-, β-, -, -, -, -globin mRNA and α-, β-, -, 
-, -, -globin transcripts have been carried out using gene-specific double 
fluorescently labelled probes in an ABI Prism 7700 Sequence Detection System 
version 1.7.3 (Applied Biosystems, Monza, Italy). The following primer and probe 
sequences were used: α-globin forward primer: 5‟-CAC GCG CAC AAG CTT CG-
3‟, α-globin reverse primer: 5‟-AGG GTC ACC AGC AGG CAG T-3‟, α-globin 
probe: 5‟-FAM-TGG ACC CGG TCA ACT TCA AGC TCC T-TAMRA-3‟; β -globin 
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forward primer: 5‟-CAA GAA AGT GCT CGG TGC CT-3‟, β -globin reverse primer: 
5‟-GCA AAG GTG CCC TTG AGG T-3‟, β -globin probe: 5‟-FAM- TAG TGA TGG 
CCT GGC TCA CCT GGA C-TAMRA-3‟;  -globin forward primer: 5‟-TGG CAA 
GAA GGT GCT GAC TTC-3‟,  -globin reverse primer: 5‟-TCA CTC AGC TGG 
GCA AAG G -3‟,  -globin probe: 5‟-FAM- TGG GAG ATG CCA TAA AGC ACC 
TGG-TAMRA-3‟; -globin (Applied Biosystems, Hs00426283_m1); -globin 
(Applied Biosystems, Hs00362216_m1) and -globin (Applied Biosystems, 
Hs00923579_m1). For real-time PCR, the reference gene was 18S; this probe 
was fluorescent-labeled with VIC (Applied Biosystems, Monza, Italy)34. 
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3 AIMS 
 
The Cell-On-CHIp biosensor (COCHISE) for detection of cell-to-cell interactions is 
a specific targeted research project which addresses integrated systems for point-
of-care diagnosis, monitoring, and drug delivery. This project is the first step of an 
activity aimed at the development of enabling micro-technologies to monitor 
physiological cellular interactions at single cell level with a high throughput. One of 
the primary applications of this technology is the immunological monitoring of anti-
tumor vaccinations, singling out the rare effector cells (in the order of 1 cell among 
1000 cells) that are actually active against tumor cells.  
The first aim within the project was to develop an appropriate platform that 
combines microfluidics and electronics together and that consists in an orderly 
matrix of up to thousand microwells where living cells can be deposited. Secondly 
the aim of this thesis was to identify a correct protocol for biocompatibility analysis 
of materials that should be subsequently chosen for biosensor manufacturing. 
After biosensor assembling, with the most biocompatible materials, it has been 
necessary to test the platform from a functional point of view, in particular the third 
intention was the development of experimental cellular systems useful to validate 
the COCHISE platform. For this purpose several proofs were performed to trap 
before beads, cluster cells and single cells from different cell lines. After 
demonstrating that the biosensor was functional and allowed to trap and recover 
single cells we have set ourselves the objective to understand whether single cells 
manipulation was a not toxic procedure, determine if the manipulated cells 
maintained their biological activity and finally if gene expression remained 
unaltered. Since the main purpose of this research is the definition of new 
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therapeutic and diagnostic protocols for tumor immunotherapy, our next step was 
to apply our technology to the analysis of anti-tumor lytic effector cells.  
In particular our aim was to demonstrate that this platform is suitable for detection 
and isolation of specific immune cells, that have shown, into the biosensor, ability 
to recognize and lyse tumor cells. On the other hand our purpose was also to 
identify and recover tumor cells that resist to CTL or NK lysis for further more 
detailed analysis and characterization from a biomolecular point of view, or to 
isolate rare steam cells. Ultimately the final goal was to develop a specific tool able 
to improve immune system response analysis in order to advance tumor 
immunotherapy.
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4 RESULTS 
 
4.1 IDENTIFICATION OF BIOCOMPATIBLE MATERIALS FOR 
BIOSENSOR MANUFACTURING 
 
 
The first aim of this study was to determine the biocompatibility of materials 
employed for the COCHISE platforms fabrication. This objective is related to the 
concept that the manipulation of single cells requires that the employed materials 
are non-toxic and defined as biocompatible. For this purpose the foils of materials 
under testing were cut in round samples (see Figure 1A) by laser: 5.7mm of 
diameter for 96-well plate and 15mm for 24-well plate. A blue-foil were used to 
cover the material during the cutting, in order to prevent surface contamination 
caused by melted material particles. Then the sample were embedded in well 
bottom of a standard multiwell culture plate with a droplet of PDMS as reported in 
Figure 1B. The PDMS was dispensed in each well by an air pressured dispenser 
(EFD, USA) with a 0,020‟ tip applying a pressure of 1.5 bar for 2.3 sec for a 96-
well plate and 13.8 sec for a 24-well plate. 
 
 
Figure 1. Materials embedding in standard multiwell plate for biocompatibility tests. (A) Materials 
are cut by laser in round samples and then (B) embedded with a PDMS droplet; PDMS was also 
used for covering the cut edges to prevent any contamination coming from the support material. 
B A 
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The dispensing parameters were defined tuning the dispensing time keeping fixed 
pressure and tip diameter. Subsequently, after the dispensing and the round 
samples deposition by a vacuum tip and applying a light pressure, PDMS was 
partially dried for 5 min at 45ºC. Finally the PDMS was fully cured at 45°C for 24h. 
An example of a 96-well plate and 24-well plate with embedded materials are 
shown in Figure 2. After obtaining the appropriate plates, biocompatibility tests 
were performed to identify suitable materials for biosensor construction. In 
particular we studied a significant number of materials, commonly used for the 
implementation of Lab-on-a-chip platforms, all materials tested are shown in Table 
1. Biological tests were performed on several cell lines (e.g. as model of cells 
growing in suspension were chosen LCLs and K562 cells, while as model of 
attached cell cultures were chosen IB3-1 and rat hippocampal primary cells) and 
on different biological functions (e.g. cell growth, erythroid differentiation of K562 
cells, CTL-mediated cell lysis and cytokine release by IB3-1 cells).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Materials embedding in standard 
96- and 24-multiwell plates for 
biocompatibility tests. The materials, cut in 
round sample, were embedded in bottom 
well of a standard 96-and 24-multiwell 
culture plate with a PDMS droplet. 
Pictures of representative multiwell plates 
were assay have been performed are 
shown. 
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   TABLE 1. Complete list of tested materials. 
Group Materials Comments and possible drawbacks Ref. 
M
E
T
A
L
S
 
Copper (Cu) 
Standard metal in a PCB; due to high chemical instability in wet environment 
is not used in bio-devices. 
12 
Palladium (Pd), 
Nickel (Ni), Gold 
(Au) 
Applied with an electroless process to a copper substrate. 
17
 
35 
Aluminum (Al) 
Widely and cheaply available as a foil; potential substitute of copper in PCB 
process flows; few nanometers of its oxide self-passivate the aluminum 
surface making it stable in wet environments. This thin protective layer can 
be overcome in electrical measurements by increasing the signal frequency. 
19
 
25
 
35 
D
IE
L
E
C
T
R
IC
S
 
Polyimide 
Used in the electronics industry for flexible PCBs or as a high-temperature 
adhesive; used as a substitute of the FR4 substrate material, typically used 
for rigid PCB devices. 
12
 
25
 
35 
 
Pyralux 
A B-stage acrylic adhesive, where B-stage means an intermediate stage in 
the cure reaction of a thermosetting resins. Used as an adhesive to create 
stacks of multiple dielectric and metal layers. Available in a wide range of 
thicknesses and in different forms: adhesive sheet itself, or coupled with 
polyimide. 
25 35 
Polyurethane 
Widely used as flexible and rigid foams, durable elastomers and high 
performance adhesives and sealants. Available either as powder and as 
films which can be applied during the lamination process. 
36 
Epoxy films filled 
with aramid fibers 
Applied as an alternative to standard glass filled epoxies used for rigid 
substrates as hole and microwell drilling by laser ablation is not possible for 
glass fiber filled materials. Patternable epoxy resins are liquid polymers 
used as adhesives or encapsulant in microelectronics. They can be applied 
by screen or stencil printing over large areas and can be also used during 
the lamination process. 
37 
Die Attach Film 
(DAF) 
Polymer film consisting of a thermosetting and UV curable resin. This 
commercially available film could also be used to spaciously laminate 
different layers together. 
38 
Poly(dimethylsilo
xane) (PDMS) 
Extensively used for fabrication of microfluidic devices. Low cost. 
Transparent down to a UV wavelength of 240 nm. Chemically inert towards 
most reagents and manufactured in multiple viscosities, thus allowing to 
achieve thicknesses in the range of microns to millimeters. Reversible 
sealing by electrostatic interaction and irreversible sealing by chemical bond 
formation is possible. The basic material is hydrophobic, but surface 
treatments by plasma etching or corona activation are very well known to 
create irreversible sealing or hydrophilic surfaces. Used as a dielectric or for 
surface treatments in PCB microfluidics devices. 
39
 
40  
A
D
H
E
S
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E
 
F
O
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S
 
Tesa 4985,  
Tesa 4983,  
CMC 15581 
Transfer double-sided tapes used for cold bonding. Available with several 
thicknesses and adhesives. 
 
 
41 
S
U
R
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A
C
E
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E
A
T
M
E
N
T
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Octadecanethiol 
(ODT) 
It is a well known self-assembled monolayer (SAM) allowing to tune the 
hydrophobicity of Au, Pl and Cu. Moreover it passivates the metal with a 
protective mono-atomic layer which, in most of the cases, is thin enough for 
not requiring an increase of the electrical signal frequency. Hydrophilic 
coating with SAM are also available, but here not tested. The ODT SAM 
presents a good thermal stability up to 50°C. 
22  23 
25 
Certonal FC-732 
 
Molding release agent and hydrophobic coating for metals and dielectrics. 
High performance anti-corrosion surface modifier; used also as an anti-
migration barrier or anti-wetting mask. Its low surface energy repels liquids 
and oils. Widely used in electronics for protection of circuit boards from 
airborne contamination and humidity, which can lead to corrosion. The dried 
film is approximately 1micron thick and thermal stable at 175°C. 
25
 
35 
Chemlease 41-90 
(Chemlease) 
 
Semi-permanent, multiple release system and is also used for molded 
applications where high chemical aggression is common, providing a 
chemical stable layer and a hydrophobic coating. 
25 35   
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4.1.1 Effects of materials on cell growth 
 
The experimental protocol for analysis of biomaterials effects on cell growth was 
the following: (a) cells (K562 or LCL) were cultured within biomaterial-treated 24 
well plates for different days (continuous exposure); (b) cells were exposed to the 
different biomaterials for 1 hour, then washed and sub-cultured in standard 
medium conditions for different days (short-term exposure). The 1 hour short-term 
exposure was chosen, since this length of time is compatible with most of the 
protocols available in literature for cellular manipulations using Lab-on-a-chip 
platforms20,34,35,42-46.  
In both continuous and short-term exposures, cell concentrations (cell number/ml) 
were determined after 3, 4, 5 and 6 days of cell growth for K562 and LCL cell 
lines. In Figures 3 and 4 the value determined after three days was reported; at 
this time, indeed, both control K562 and LCL cells are in the log-phase of cell 
growth, allowing the best comparison to detect cell growth inhibition in 
experiments aimed at studying possible inhibitors of cellular proliferation47. 
However similar results were obtained also at day 4, 5 and 6 (data not shown). 
The effects of the employed materials were considered as inhibitory effects in the 
case of 75% inhibition of cell proliferation, in consideration of the fact that inhibition 
around 50% of cell growth might be associated in K562 cells, instead to cytotoxic 
effects, to activation of terminal erythroid differentiation27. Results of these 
experiments are shown in Figures 3 and 4. In particular, in Figure 3, the data 
obtained, allow to conclude that continuous exposure to materials is not 
compatible with efficient cell growth, for the following materials: Cu, Au over Ni, Au 
over Pd (metals), Cu + ODT, Au over Pd + ODT (surface treatments), Pyralux 
uncured, DAF, aramid fiber uncured, Tesa 4985 (dielectrics/adhesives). In fact 
these materials inhibited cell growth of both K562 and LCL cells. Epoxy cured, 
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instead, was inhibitory only on LCL cell growth. Therefore, very consistent effects 
were obtained on these two cellular systems when continuous exposure to the 
tested materials was undertaken. 
When exposure was limited to 1 hour (Figure 4), most of the materials displayed 
no inhibitory activity, with the exception of aramid fiber uncured (which maintained 
the inhibitory activity on both cell lines) and DAF, Cu and Cu+ODT (which 
maintained the inhibitory activity only on LCL cells). Interestingly, Pyralux cured 
renders Pyralux compatible with cell growth (see Figures 3 and 4B). In addition, 
aramid fiber cured was found to be not active in inhibiting cells growth with the 
exception of long-time treated LCL cells. These data indicate that caution should 
be taken when using uncured Pyralux and aramid fibers for the construction of 
Lab-on-a-chip platforms.  
Similar results, as shown in Figure 5, were obtained in another cell line: IB3-1. 
Ultimately the achieved results firmly demonstrate that some materials exhibited 
strong inhibitory effects on most of the cell lines and biological functions assessed. 
When long-term exposure was carried out uncured Pyralux, printable epoxy fully-
cured, Au over Ni, Au over Pd, Au over Pd+ODT, Cu and Cu+ODT inhibited 
biological functions. Aluminum and palladium were found to be not cytotoxic in 
most of the assays employed. Preparation of the materials appears to be a critical 
point. In this sense, both uncured preparation of Pyralux and aramid displayed 
inhibitory activities in several assays, while cured Pyralux and cured epoxy films 
with aramid fibers did not. Ultimately with these assays has been demonstrated 
that most of the selected materials can be used for a short exposure of the cells, 
with the exception of Cu, Cu+ODT and aramid uncured.  
A complete list of the tested materials and their effects on cell growth are 
summarized in detail in Table 2. 
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Figure 3. Effects of the materials on cell proliferation of K562 and LCL cells after continuous 
exposure. K562 cells (A) or LCL cells (B) were cultured in RPMI, 10% FBS for different days in 
24 well plates containing the indicated materials. The cell number/ml was determined and 
compared with control untreated cells cultured in standard conditions. The data reported in the 
Figure represent cell proliferation in respect to control cells (average  SD from three different 
experiments). The cell number/ml was evaluated after 3 days, when both K562 and LCL cells are 
in the logarithmic phase of cell growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effects of the materials on cell proliferation of K562 and LCL cells after short-term (1 
hour) exposure. K562 cells (A) or LCL cells (B) were exposed in RPMI 10% FBS for 1 hour in 24 
well plates containing the materials. After two washing steps with RPMI, cells were sub-cultured in 
standard conditions. The cell number/ml was determined and compared with control cells after 
three days of cell culture. The data represent the average  SD from three different experiments. 
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Figure 5. Effects of the materials on cell proliferation of IB3-1 cells. (A) continuous exposure; (B) 
short-term exposure. The cell number/ml was determined and compared with control cells after 
three days of cell culture. The data represent the average  SD from three different experiments. 
 
              
  Continuous exposure Short exposure 
   LCL K562 IB3-1 LCL K562 IB3-1 
M
e
ta
ls
 
Cu x x x x - x 
Al - - - - - - 
Pd - - x - - - 
Au over Ni x x x - - - 
Au over Pd x x - - - - 
D
ie
le
c
tr
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s
-a
d
h
e
s
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s
 
PI - - x - - - 
Py uncured x x x - - - 
Py cured - - x - - - 
PDMS - - x - - - 
PF before lam - - x - - - 
PF after lam - x x - - - 
PP - - x - - - 
Epoxy cured x - x - - - 
DAF  x x x x - - 
Aramid fiber cured - - x - - - 
Aramid fiber uncured - x x - x x 
Tesa 4983 - - - - - - 
Tesa 4985 - x x - - - 
CMC 15581 - - - - - - 
S
u
rf
a
c
e
 t
re
a
tm
e
n
ts
 Cu + ODT x x x x - x 
Pd + ODT - - - - - - 
Au over Ni + ODT - - x - - - 
Au over Pd + ODT x x - - - - 
Certonal FC-732 - - - - - - 
Certonal FC-732T - - - - - - 
Chemlease - - - - - - 
Table 2. Tested materials and their effects on in vitro cell growth. 
(- =no effects; x = inhibition) 
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4.1.2 Effects of materials on erythroid differentiation 
 
The analysis of the effects of the materials on differentiated functions of K562 cells 
was performed by determining the proportion of benzidine-positive (hemoglobin 
containing) K562 cells treated with mithramycin, a powerful inducer of erythroid 
differentiation. The results obtained, both for continuous and short-term 
exposures, are shown in Figure 6, and clearly indicate a full suppression of 
percentage increase of benzidine-positive cells with respect to control erythroid 
induced cells (K562 cells treated with 25 nM mithramycin) after a continuous 
incubation (long exposure) with the following materials: Cu, Au over Pd, Au over Ni 
(metals), Cu+ODT, Au over PD+ODT (surface treatments), Pyralux uncured, DAF, 
aramid fiber uncured, Tesa 4985 (dielectrics-adhesives).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Effects of the materials on erythroid differentiation of mithramycin-induced K562 cells 
during (A) continuous exposure or (B) after short-term (1 hour) exposure with the different 
materials under  investigation. The proportion of benzidine-positive cells was determined after 6 
days of cell culture. In our experiments, uninduced cells displayed 0.5%  2 of benzidine-positive 
cells. Control mithramycin-treated cells exhibited always very high values of benzidine-positive 
cells (92%  5.5). The results are presented as % of differentiated cells in respect to control 
mithramycin-treated cells (considered as 100%). The data represent the average  SD from three 
different experiments. 
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In the case of a short exposure (1 hour), Cu and aramid fiber uncured induced a 
strong reduction of the percentage of benzidine-positive cells; also Au over Pd and 
Cu + ODT exhibited inhibitory activity, although to a lesser extent. 
These data are fully in agreement with the results obtained in the cytotoxic and 
antiproliferative tests (Figures 3A and 4A). 
 
4.1.3 Effects of materials on cytokines release by IB3-1 cells 
 
The cystic fibrosis IB3-1 cell line was chosen, unlike the other lines previously 
analyzed, as a representative example of adherent growing cells. Furthermore 
IB3-1 cells were employed as a model system releasing several cytokines and 
chemokines as indicators of their differentiated state. As a consequence the 
analysis of the effects of materials on IB3-1 biological function were evaluated 
measuring the amount of cytokines released by cells after continuous or short 
incubation with different materials. Results obtained were in line with data showed 
for erythroid differentiation. In particular some cytokines profile (e.g. IL-1alpha, M-
CSF, GRO-alpha, ICAM-1) were changed by  Cu, Au over Ni, Cu+ODT, Au over 
PD+ODT, DAF, aramid fiber uncured, and Tesa 4985 after continuous incubation. 
However when exposure was limited to 1 hour only Cu, Cu+ODT and aramid fiber 
uncured induced a significant variation in cytokine release profile, while slightly 
changing were noticed for all the other materials (data not shown). 
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4.1.4 Effects of materials on CTL-mediated lysis of LCL cells 
 
The analysis of the effects of the biomaterials on CTL-mediated lysis is shown in 
Figure 7, in particular it indicates that CTL-mediated lysis is detectable using all 
the biomaterials analyzed, with the exception of Tesa 4985. The values of the 
percentage of lysis, in fact, were in all cases very similar to those of the control, 
represented by untreated cells (Figure 7A). However some tested materials 
caused increase background levels (spontaneous release) of LCL lysis, including 
Cu, Cu+ODT, Tesa 4985 and aramid fiber uncured (Figure 7B). Interestingly, Cu, 
Cu+ODT, Tesa 4985 and uncured epoxy filled with aramid fiber are materials 
exhibiting antiproliferative activity on LCL cells, as reported in detail in Figures 3B 
and 4B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effects of biomaterials on CTL-mediated lysis. 
51
Cr-labelled LCL cells were incubated 
for 5 hours with CTL in a CTL:LCL ratios of 10:1 in 96 well plate with different materials. Incubation 
for 5 hour was performed in order to compare the effects of the employed materials with optimal 
CTL-mediated lysis of LCL. (A) % lysis ratio CTL:LCL 10:1. (B) % spontaneous release (sample - 
control). 
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4.2 BIOSENSOR CHARACTERIZATION 
 
One of the purposes of this thesis was the development of experimental cellular 
systems useful to validate the biosensor functionality. In particular our focus was 
the manipulation of single cells using the available COCHISE platform, performed 
with the following specific aims: (a) determine whether this procedure is feasible 
initially with beads and after with cells, (b) verify if COCHISE platform is suitable to 
allow interaction between cluster cells e.g. target and effector cells, (c) find out if 
biosensor could be used for identification of active immune system cells like CTLs 
or NKs.  
 
4.2.1 Beads, cells and cells group levitation and trapping 
 
Initially the first evidence of trapping was carried out using polystyrene beads. This 
trapping was possible both in physiological medium and in DI water at frequencies 
ranging from 100KHz to 2MHz. 90µm polystyrene beads were trapped in an up-
scaled device with a 300µm well filled with DI water with a signal amplitude of 18V. 
When loading beads in the microwell from the top with load configuration active, 
the electric field minimum is represented by a circular region along the well 
boundary at the level of MID electrode and particles are levitated by nDEP in 
random positions within this region (Figure 8A). After switching to trap 
configuration, beads move to the central spherical cage (Figure 8B). Reducing the 
microwell diameter to 125µm, smaller beads with a diameter of 25µm were 
successfully controlled in the microwell. Successively other trapping and levitation 
tests were conducted with K562 cell line. Initially K562 were too small in diameter 
(15-20µm) so there were some trouble in trapping them inside the well thus we 
decided to treat K562 cells with 1μM cytosine arabinoside (AraC). This treatment 
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induces an increase in cell diameter, so we were able to trap the cells (Figure 8C). 
Other experiments were conducted in order to identified ideal parameters that 
allowed manipulation of small size cells, in particular modifying well diameter and 
frequency range also K562 wt were successfully trapped inside the biosensor. 
Cells delivery was performed either manually or by use of a microdispenser, by 
spotting them into the well from top and with the load configuration active. Single 
cells or small clusters were successfully kept levitating in the microwell in load 
mode at the level of central electrode in random positions along the well boundary. 
After switching to trap mode, cells were moved towards the center of the well and 
maintained in this position until the application of the eject mode. 
  
 
 
 
 
Figure 8. (A) Two polystyrene beads are first levitated in load mode (B) and then made interact by 
setting the microwell in trap mode. Hole diameter: 300µm, Bead diameter: 90µm, Voltage 
amplitude: 18V; (C) a single K562 cell, previously treated with 1μM cytosine arabinoside (AraC), 
trapped in the center of a microwell filled with physiological medium. Hole diameter: 125µm. 
 
 
4.2.2 Analysis of cell to cell interaction 
 
The manipulation of single cells and particles, and the analysis and monitoring of 
cell-to-cell interactions, is of great interest in various areas of the life sciences 
ranging from immunotherapy and cancer research, to rare cell identification and 
isolation. The main requirements for a biotechnological platform supporting these 
features are: 
 Cell delivery in predefined locations as to force cell-to-cell interactions 
 Single cell trapping and manipulation 
 Recovery of selected cells 
A B C 
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 High throughput allowing multiple interactions to be activated in parallel 
 Support for automated fluid handling 
All these requirements are accomplished, in our biosensor, by electrically active 
microwells, based on microwells open at both top and bottom, where single cells 
can be trapped by means of negative dielectrophoresis (nDEP). Comparing to 
Lab-on-a-chip solutions based on single fluidic chambers or channels, the main 
advantage of this approach is the isolation of cells in separate sites with a support 
for flexible supernatant substitution and easier single-cell recovery procedures, 
guaranteeing mechanical compatibility with standard high-density microtiter plates. 
Since one of our goal is to employed the biosensor for immune system studying, 
and whereas it is composed of different cells in size, we demonstrated first that 
cells with different diameters could be trapped inside the same microwell, and then 
that they could be force to interact together. In particular some representative data 
of cells-trapping and cell to cell interaction are shown in Figure 9. 
 
 
 
 
 
 
 
 
 
 
Figure 9. Trapped cells inside the same microwell and cells induced to interact together.  
(A) Image of two K562 cells trapped in a 70um microwell by optical microscope; (B) Image of four 
calcein-labelled K562 cells trapped in a 70um microwell by fluorescence microscope; (C) Image by 
optical microscope of cluster cell with different diameters (LCLs calcein-labelled and CTLs) that 
levitate together in the same microwell; (D) Image by fluorescence microscope of cluster cells 
where only calcein-labelled LCLs are visible.  
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4.2.2.1 Evaluation of CTL mediated lysis 
 
In order to validate the biosensor, generation of EBV-EBNA1-derived specific 
cytotoxic T-lymphocytes was performed. In particular HPV specific CTLs were 
obtained from monocyte-depleted PBLs from EBV-seropositive donors stimulated 
with synthetic peptide HPV (HPVGEADYFEY from EBNA1–EBV protein, aa 407-
417). The specificity of CTL cultures was tested after three stimulations using 
standard 51Cr release assays against autologous PHA-blasts, pulsed or not with the 
synthetic peptide. For analysis of CTL-mediate lysis, through biosensor, LCL cell 
line was employed as target cells. The first control experiment on LCL cells is 
depicted in Figure 10B and demonstrated the possibility to isolate single LCL in a 
microwell and to assess its viability. Calcein fluorescence of target LCL cells was 
tested inside the device for more than 45 minutes.  
 
 
Figure 10. Biosensor validation. (A) Image of a microwell within LCLs and CTLs; in the next panel 
lysis of three peptide-loaded LCLs by CTLs is shown, the lysis of these cells, shown by calcein 
disappearance, happen in 20 minutes. (B) Viability of one single calcein-labelled LCL trapped into 
the biosensor microwell, calcein fluorescence of this cell is stable for more than 45 minutes. 
Pictures has been taken every 5 minues.  
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These results have firmly demonstrated that calcein fluorescence of target cells 
was stable within the COCHISE device, rendering feasible the analysis of CTL 
mediated cell lysis leading to calcein loss from target cells. 
In a typical experiment aimed at determining CTLs activity, CTLs were delivered in 
microwells when three LCL (Figure 10A) or single LCL (Figure 11A) cells have 
been previously deposited. In particular, in these figures, pictures show calcein 
disappearance in LCL pre-loaded with synthetic peptide and consequently 
demonstrate the lysis of these cells by the surrounding CTLs. Repeated 
experiments indicate that the lysis happen between 10 and 15 minutes. Also LCL 
not loaded with synthetic peptide has been considered as control, in this case 
CTLs did not lyse these target cell and as shown in Figure 11B calcein 
fluorescence of target cells was stable. 
 
 
Figure 11. Biosensor validation. (A) One LCL pre-loaded with synthetic peptide surrounding by 
CTLs, the lysis of this cell shown by calcein disappearance happen in 20 minutes. (B) LCLs not 
loaded with synthetic peptide has been considered as control, in this case CTLs did not lyse these 
target cell in fact calcein fluorescence of target cells was stable more then 20 minutes. Pictures has 
been taken within biosensor microwells at different time point as indicated. 
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4.2.2.2 Evaluation of NK mediated lysis 
 
In addition, to analyze cell to cell interaction, NKL cells were employed exhibiting 
(a) differential lytic properties and (b) possibility to be identified by antibody-
antigen interactions. For NK-mediated lysis, two tumor cell lines were utilized: the 
221 and 221-G1 lymphoblastoid cells. NKL cells were able to lyse the 221 cells, 
but unable to efficiently lyse 221-G1 cells; NK-YTS (YTS) cells, instead, were able 
to lyse with high efficiency both 221 and 221-G1 cells. Control experiment were, 
obviously, conducted on calcein stability of trapped target cells 221 or 221-G1. 
Obtained data demonstrate that calcein was stable more then 1h, suggesting that 
the device is suitable for NK cytolytic assay. Figures 12A and 12B demonstrate 
that NK-mediated lysis is detectable into COCHISE biosensor using the 221 cell 
line as target and both NKL and YTS cells as effectors respectively. In particular 
these data firmly demonstrate that the biosensor is suitable for real-time detection 
of single target cells lysis by CTLs (Figure 11A) and NKs (Figure 12) cells. 
 
     minutes 
 
 
Figure 12. Biosensor validation. (A) NK-mediated lysis of  calcein-labelled 221 cells (B) NK-YTS 
mediated lysis of calcein-labelled 221 cell. Pictures has been taken within biosensor microwells at 
different time point as indicated. 
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4.3 BIOTECHNOLOGICAL SENSOR VALIDATION 
 
Other aims of this work were to determine if cell isolation procedure was not toxic, 
to find out if manipulated cells maintained their biological activity and finally to 
compare data obtained with the biosensor to other technologies.  
 
4.3.1 Isolation and in vivo expansion of single cells  
 
Our study was keeping on in order to determine biosensor functionality about 
isolation and single cells recovery. In particular K562 cells were used to perform 
several recovery experiments. For this purpose, cells were washed twice and 
resuspended in NaCl 0,9% sterile solution to a final concentration of 1 to 5x105 
cells/ml. Using a peristaltic pump, at a speed of 8 l/min, cells were fluxed in the 
channel from a reservoir to the device inlet and, when the channel was full, the flux 
was stopped to permit cells to fall down inside the holes. Concentration of 1x105 
cells/ml allows to achieve 1 cell/hole. Subsequently cells reservoir was replaced 
with a new one with NaCl 0,9% sterile solution, and finally the device were rinsed 
for at least 20min to remove every cell inside the channel before the recovery 
procedure. Cells recovery were performed using an electrovalve connected to the 
device from inlet and outlet with pulse of 5msec on a 96well microtiter aligned with 
the device and filled with RPMI+10% FCS. As shown in Figure 13, clonal 
expansion of recovered single cells were subsequently conducted in 96well plate 
until a sufficient cells number was available to perform other biological assays.    
 
 
 
Figure 13. A single K562 recovered from biosensor into a 96well plate. First picture shows a single 
K562 (signed by white arrow) inside 96well plate, other photos show clonal expansion of recovered cell 
after 72h and 120h. 
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4.3.2 Biological characterization of isolated clone 
 
The analysis of the effects on K562 manipulation in the biosensor was performed 
analyzing cells growth (proliferation) and erythroid differentiation, after recovered 
cells clonal expansion. The results of cell proliferation in K562 and in K562 
manipulated in Lab-on-a-chip (LOC K562) are summarized in Figure 14 and 
displayed an analogue pattern of growth both in treating with mithramycin28 and 
AraC, two inducers of erythroid differentiation, and in standard condition without 
treating. For mithramycin has been chosen different treating concentration (20nM, 
40nM, 80nM) while for AraC has been selected a single treatment at concentration 
that induce the best erythroid differentiation (500nM).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Analysis of the effects of cell manipulation on K562 cells growth. Cell growth 
(proliferation) was studied by determining the cell number/ml after 3, 4, 5 and 6 days of cell culture.  
The experiment was performed by treating the cells with 500nM AraC or without treating (NT), 
upper panel; or treating cells with 20nM, 40nM or 80nM mithramycin (Mithra) lower panel. (A-C) 
data obtained in K562; (B-D) data obtained in LOC K562. The data represent the average  SD 
from three different experiments. 
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The analysis of the effects on erythroid differentiation of K562 cells was performed 
by treating control and recovered cells with mithramycin (20nM, 40nM, 80nM) and 
with 500nM AraC. After 3 to 6 days culturing with this two differentiation inducer, 
the proportion of benzidine positive (erythroid hemoglobin-containing) cells was 
analyzed using the benzidine-test. The results reported in Figure 15 have shown 
the same percentage of benzidine-positive in LOC K562 cells respect to control 
(K562 cells not manipulated) both with mithramycin, at the different 
concentrations, and with 500nM AraC. These results demonstrate that cell 
manipulation in the biosensor do not interfere in K562 biological functions, so this 
validation shows that biosensor could be used for cells recovery and isolation for a 
subsequent cell culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Effects of cells manipulation on erythroid differentiation in K562 cells. The experiment 
was performed by treating (A) K562 and (B) LOC K562, or not (NT) with 20nM, 40nM or 80nM 
mithramycin and with 500nM AraC. The proportion of benzidine positive (erythroid hemoglobin-
containing cells) was analyzed using the benzidine-test after 3 to 6 days culturing. The data 
represent the average  SD from three different experiments. 
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4.3.3 Analysis of gene expression after single cell manipulation  
 
Afterwards our attention has been focused on the analysis of gene expression in 
recovered cells. In particular globin genes expression were assayed in K562 not 
manipulated and LOC K562 after treatment with a strong differentiation inducer, 
referred as AA55. For this purpose cells were treated for 5 days with 50 M AA55; 
at this time both K562 and LOC K562 reached a 98% of erythroid differentiation 
analyzing with benzidine-test (Figure 16). Subsequently cells were pelleted and 
total RNA was phenol–chloroform-extracted from cytoplasm.  
 
 
 
 
 
 
 
 
 
 
 
 
Successively, to identify any differences in globin genes expression, a quantitative 
real-time PCR assay of α-, β-, -, -, -, -globin transcripts were carried out using 
gene-specific double fluorescently labelled probes. Q-RT-PCR amplifications were 
performed on RNA from untreated or treated cells using primers amplifying 18S 
ribosomal RNA as reference gene. These data demonstrate no significant 
differences in globin mRNAs content in K562 and in LOC K562 cells (Figure 17), 
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Figure 16. Erythroid differentiation of K562 and LOC K562 treated with 50 M AA55. The 
proportion of benzidine positive (erythroid hemoglobin-containing) cells was analyzed using the 
benzidine-test after 3 to 5 days culturing. 
RESULTS                                                                                                                                    Part I 
 52 
so we could affirm that cell manipulation into biosensor do not interfere in globin 
genes expression. These are preliminary data but other extensive experiments 
about different genes expression will be performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Quantitative real-time PCR assay on α-, β-, -, -, -, -globin genes expression in K562 
and LOC K562. After recovery, LOC K562 and control cells were treated with 50 M AA55 for 5 
days, total RNA was phenol–chloroform-extracted from cytoplasm and Q-RT-PCR were performed 
for all globin genes; fold increased were evaluated respect to untreated cells. The data represent 
the average  SD.  
 
 
4.3.4 Comparison between biosensor platform and BioStation 
 
In this part of the study we wanted to compare lysis data achieved by biosensor 
technology and data obtained with BioStation IM instrument (Figure 18A). In 
particular this last technology is a compact system that consist in a cell incubation 
and monitoring system that allows sophisticated time-lapse imaging with a highly 
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integrated microscope and cooled CCD camera. The BioStation IM moreover 
facilitates a broad array of long term time-lapse experiments, including studies of 
cell growth, morphology, and protein expression, by providing consistent 
environmental control of temperature, humidity and gas concentration in 
combination with phase and fluorescence imaging. 
For the comparison between the two platform, the same cellular systems, 
previously exploited, were chosen. In particular NKL (NK) and NK-YTS were 
utilized as effector cells while LCL 221 and LCL 221-G1 were calcein marked and 
used as target cells. All effector : target combinations and their respective controls 
were seeded in specialized Hi-Q4 culture dish (Figure 18B). These plates are 
divided into four segments in order to permit multi-sample observation. Afterwards 
long time-lapse phase and fluorescence imaging were taken for each sample to 
analyze specific lyses and controls.  
 
 
 
 
 
 
 
                               Figure 18. (A) BioStation IM (B) Specialized Hi-Q4 culture dish. 
 
Some representative effector : target lysis assays performed into BioStation are 
shown in Figure 19. In particular in Figure 19A and 19B are depicted the 221 lysed 
by NK-YTS while in Figure 19C and 19D are reported 221 cells lysed by NK. 
These assays have specifically shown that target cells lysed by NK-YTS or NK cell 
lines assessed in BioStation IM system were essentially such as that shown in 
dielectrophoretic platform (Figure 12), suggesting that the biosensor is suitable to 
A B 
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study cell to cell interactions. The advantage of COCHISE platform is the ability to 
analyze single cells lysis and, if necessary, a subsequent recovery of particularly 
active effector cells could be done; unlike with BioStation we can monitor single 
cells lysis too, but in presence of other cells inside the plate. To work on single 
cells would be necessary to plate target and effector using limiting dilution, but the 
problem then would be the difficulty to rich correct cell to cell interaction. However 
the major limitation for BioStation technology remains recovery that cannot be 
performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. (A-B) 221 target cells lysed by NK-YTS and (C-D) 221 target cells lysed NK cell lines, 
assessed into BioStation. 
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5 DISCUSSION 
 
Lab-on-a-chip (LOC) platforms are integrated semiconductor devices that serve as 
a laboratory for the testing and analysis of very small chemical and clinical 
samples. Normally, these instruments and analytical devices consist of a network 
of channels that are built on a semiconductor die for use as a micro or nano lab. In 
this thesis a specific Lab-on-a-chip platform for analysis of cell to cell interaction 
has been considered from its design, construction and validation. The platform 
developed within the project consists of an orderly matrix of up to 1536 microwells 
where living cells can be deposited. The platform is created in a biocompatible 
substrate that also serves as a high-density circuit board. The microwells are 
monitored by an external microscope, the electronics allow to control the 
biosensor electrodes, necessary to DEP forces induction, and to perform 
impedance measurements. The key point is that each microwell can force contact 
between individual cells, and detect consequences of these interactions.  
The accurate analysis of the biological effects of materials used for construction of 
LOC platforms for cells manipulation is an essential pre-requisite in order to 
develop devices for biomedical and biotechnological applications. Therefore, as 
first purpose, the analysis of biomaterials effects on biological functions have been 
analysed on: (a) K562 cells induced to erythroid differentiation and production of 
haemoglobin by mithramycin; (b) CTL mediated LCL-lysis; (c) human IB3-1 
tracheal cells producing a variety of interleukins and cytokines; and (d) rat 
hippocampal cells differentiating in neurons and astrocytes (in collaboration with 
the Department of Clinical and Experimental Medicine, Section of Pharmacology 
and Neuroscience Center, University of Ferrara). We have conclusively and 
reproducibly analysed all the selected materials, for biosensor manufacturing, 
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using long-term exposures, supporting the conclusion that among the 26 tested 
materials (7 employed in surface treatments, 14 dielectrics/adhesives, and 5 
metals) some display strong inhibitory effects on biological functions. When the 
results obtained on cell growth parameters and biological functions are considered 
together it can be concluded that all materials can be used for a short exposure to 
cells, with the exception of aramid fiber uncured, Cu, Cu+ODT and, to a lower 
extent, Au over Pd and DAF. Therefore, the use of these materials should be 
avoided, even if the device under construction is designed for short-term cell 
exposure, for instance in the case the Lab-on-a-chip platforms is simply dedicated 
to cell manipulation, isolation and sub-culturing. Of great importance for this 
project are the biocompatibility results obtained using CTLs as experimental model 
system. The results achieved support the concept that all materials are compatible 
with this biological activity for a short exposure, except aramid fiber filled epoxy 
uncured, Cu and, to a lower extent, Cu+ODT, Au over Pd and Tesa 4985. 
Therefore, since the most part of the tested materials did not negatively affect the 
considered biological functions, it has been demonstrated that PCB technology, 
with some limitations, is suitable for the realization of LOC devices well compatible 
at least for analytical purposes.  
Once identify the most biocompatible materials in each analyzed group, the 
engineers (from ARCES-University of Bologna, in collaboration with the other 
project partners) developed some LOC prototypes that consecutively have been 
validated in our laboratories. First beads have been trapped inside the biosensor 
by DEP and, after modifying some parameter like well diameter and signal 
amplitude, also cluster or single cells have successfully been trapped and levitated 
into the platform. Viability of deposited and retrieved cells by this platform was 
successively demonstrated, showing biosensor functionality. 
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An important side of this research is, in particular, the definition of new therapeutic 
and diagnostic protocols for cancer immunotherapy. As a first step, we applied our 
technology to the analysis of anti-tumor lytic effector cells, for a precise detection 
of lytic events which happen into the device at certain locations and timings. A 
major advantage of the biosensor is that the cells trapped are kept alive and can 
be retrieved individually for further analysis, such as gene expression profiling or 
simply for cell amplification. 
In particular it has been demonstrated that LOC platform, designed in this project, 
is suitable for single cell lysis monitoring (e.g. tumor cell lysis by CTL or NK 
effector cells) and, what is most important, that we could identified the precise well 
in which specific tumor cell lysis is achieved and recover active CTLs or NK cells 
for further analysis. Comparison between data obtained with COCHISE platform 
and BioStation has shown that target cells lysis by different immune effector cells 
assessed with these two monitoring system were essentially similar, suggesting 
that this new device is suitable to study cell to cell interactions. Furthermore the 
great advantage of the biosensor is the capability to analyze single cells lysis and, 
if required, a subsequent cell recovery could be achieved, unlike with BioStation 
where these actions could not be performed.  
The results obtained, during this project, represent a significant step in the 
development and implementation of an innovative tool that will allow important 
future progresses in cancer diagnosis and therapy. The possibility to manipulate 
the immune system to recognize and kill tumor cells is very attractive despite 
numerous obstacles remaining to be overcome, such as tolerance and tumor 
escape. In particular, the ability of the immune system to seek out and destroy 
disseminated micro-metastases in a specific way makes immunotherapy an 
attractive alternative or complement to conventional therapies. Today patients are 
treated with biological substances such as interferon, interleukin-2 or other factors 
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to stimulate and activate an immune response against tumor cells. These drug, 
however, are not always well tolerated and may cause adverse effects leading to 
discontinuous treatments. An alternative approach is to identify specific tumor-lytic 
CTLs that recognize and lyse cancer cells, their amplification in vitro, in presence 
of specific growth factors, and finally their re-injection into the patient. One of the 
main problems related to this approach is the identification and isolation of the 
very small number of cells that are selectively able to kill tumor cell. Nevertheless 
the platform designed in this project, although with some limitations, can be used 
for this purpose.  
In conclusion this study is aimed at developing a new class of biosensors, 
produced with biocompatible materials, and able to detect interactions between 
single immune effector cells and tumor cells, for identification of tumor-specific 
CTLs. The development of these biosensors is designed to improve the possibility 
to find out effective cancer treatment. Many promising technologies for tumor 
immunotherapy, currently, have different limitation in their use for the difficulty of 
isolating and acquiring information on biologically active immune cells and tumor 
cell resistant to CTL-mediated lysis. This technology, instead, with some 
improvements, should permit to reach such information at a reasonable cost, 
quickly and without any complex laboratory equipment. 
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1 INTRODUCTION 
 
1.1 IMMUNE SYSTEM 
 
Viruses are obligate intracellular organisms that replicate inside cells, exploiting 
host biosynthetic pathways. The viruses infect a wide range of cellular targets 
using as receptors molecules that are normally expressed on cell surface. After 
their entry into the host cell, they can cause tissue damage and disease through 
several mechanisms. In particular viral replication can interfere with normal cellular 
functions, such as protein synthesis, leading to damage and ultimately to cell 
death (lytic infection). Some viruses also have the ability to induce latent infection, 
during this phase they remain inside the host cell producing proteins that can, in 
some cases, altering cell functions. To control viral infections and eliminate 
infected cells, the immune system responds through innate and cell-mediated 
immunity. The main mechanisms of innate immunity are the block of infection by 
production of type I interferon (IFN) and lysis of infected cells by natural killer 
lymphocytes (NK). The latter mechanism represents an important defence during 
the early stages of infection before intervening specific responses. Specific 
immunity, instead, is mediated by antibodies and cytotoxic T lymphocyte (CTL). 
Specifically, antibodies prevent virus interaction with target cells and its 
penetration inside host cells, while T lymphocytes eliminate infection reservoir by 
killing infected cells. 
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1.1.1 T lymphocytes 
 
Cytotoxic T lymphocytes are immune system cells with a key role in recognition 
and elimination of tumor cells or virus infected cells. They are able, through their 
surface T cell receptor (TCR), to recognize antigens presented on specialized 
antigen presenting cells (APCs) surface, in association with molecules of the Major 
Histocompatibility Complex (MHC)48 (Figure 1A and 1B). Each T cell expresses a 
TCR with a single antigen specificity. This receptor consists of two polypeptide 
chains, called α and β chains linked by a disulfide bond in the peptide portion 
anchored to the membrane. CTLs recognize antigens (small peptide of about 8-10 
amino acids in length) derived from viral or tumor protein degradation by cytosolic 
enzymes and in particular by proteasomes (see 1.1.2 paragraph). For a successful 
recognition these antigens are successively transported into the endoplasmic 
reticulum by TAP transporters, loaded on MHC class I molecules and expressed 
on cell surface where they are definitively presented to CTLs.  
 
 
 
 
 
 
 
 
 
 
Figure 1. (A-B) Recognition of antigenic peptide mediated by interaction between MHC-I/peptide 
complex, exposed in antigen presenting cell (APC), and T cell receptor (TCR) of T CD8+ cell. (C) 
Killing of infected target cells by cytotoxic T lymphocyte through exocytosis of perforins-containing 
granules. 
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The interaction between MHC-I/peptide complex and TCR receptor, together with 
interaction of other costimulatory molecules expressed on APC surface and 
accessory molecules in T cell surface, actives CTL mediated lysis (Figure 1C).  
In particular, CTLs  kill their cellular target mainly via three mechanisms48:  
1) exocytosis of granules containing perforin, a pore forming protein, that 
polymerize on the target cell membrane causing osmotic cell lysis;  
2) entry through open pores, generated by perforin, of serine proteases 
(granzymes) that induce apotosis in target cells;  
3) expression of Fas ligand (FasL) that interacts with Fas molecules present on 
target cell, leading to activation of apoptotic pathway. 
 
1.1.2 Proteasome and antigen processing 
 
The proteasome is a big, barrel-shaped, multi-subunit protease complex consisting 
of a 19S regulatory particle (or cap) and a 20S core particle49. The 20S core 
consists of 28 subunits,  two -heptamers forming the outer rings, and two -
heptamers forming the inner rings of core particle (Figure 2). The α-subunits 
create a channel that allows the polypeptide chains entry into the proteolytic 
chamber50,51.  
 
 
 
 
 
                                                   
 
Figure 2. Proteasome structure. 
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This access route for proteins assumes open- or closed-conformation depending 
on its association with regolatory subunits and ATP presence. Hole diameter 
allows the entry of denatured proteins only. The proteasome proteolytic activities 
reside in the -heptamers subunits; in particular 1, 2, 5 subunits display 
different cleavage specificities refereed to as chymotrypsin-like ( 5), trypsin-like 
( 2) and caspase-like ( 1)50,51. Upon complete assembly of the core 20S, the N-
terminal extensions of the three -subunits are automatically removed to allow N-
terminal threonine exposure as active-site nucleophile.  
 In higher eukaryotes under  interferon-  stimuli the three catalytically active  
subunits 1, 5, and 2 are replaced with LMP2, LMP7 and MECL1 
immunosubunits respectively; moreover the 19S cap is replaced by PA28 (11S) 
particle51 (Figure 3). This proteasome, called immunoproteasome, displays an 
increased peptide production efficiency and has a key role in the generation of 
antigenic peptides that are associated with MHC class I molecules and presented 
to cytotoxic T lymphocyte50,51. Therefore the proteasome beyond to consent 
damaged proteins and regulatory proteins degradation, has a crucial role in the 
generation of antigenic peptides, playing an important part in the antigen 
processing. However other several cytosolic proteases have been implicated in 
the generation of antigenic peptides for MHC class I, such as leucine 
aminopeptidase52, hydrolases and tripeptidyl-peptidase II (TPPII)53.  
 
 
 
 
 
 
 
        Figure 3. The switch from proteasome to immunoproteasome under IFN-  treatment. 
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For protein degradation by the proteasome, firstly is required protein conjugation 
with a poly-ubiquitin chain. Ubiquitin is a small globular protein highly conserved of 
8 kDa and consisting of 76 aa50,51. 
Furthermore the proteins have to present signals that activate ubiquitin pathway. 
In particular these signals are: 
1) the presence of specific N-terminal amino acid (N-end rule): protein with N-
terminal amino acid charged or with voluminous residues (e.g. Phe, Leu, Tyr, Trp, 
Lys and Arg) are rapidly ubiquitinated and then degraded, proteins with amino acid 
containing small residue in N-terminal are quite stable; 
2) phosphorylation of the substrate to be degraded; 
3) substrate denaturation with consequent exposure of hydrophobic surfaces;  
4) association with an ancillary protein. 
 
1.1.3 MHC class I molecules 
 
The Major Histocompatibility Complex (MHC) in humans, also known as Human 
Leukocyte Antigen (HLA), is controlled by genes located on chromosome 6. It 
encodes cell surface molecules specialized to present antigenic peptides to T 
cells. MHC molecules are divided into two main classes: class I and II. MHC class 
I are cell surface glycoproteins present on all nucleated cells. They are 
heterodimers of a heavy chain, a 45kDa type I integral membrane glycoprotein, 
and β2-microglobulin (β2m), a 15 kDa soluble protein (Figure 4). The heavy chain 
is encoded by genes at the HLA-A, HLA-B, and HLA-C loci. The extra cellular 
region of the heavy chain folds into three domains, ( 1, 2 and 3), with β2m 
contributing of a fourth domain. The 1 and 2 domains form the peptide-binding 
site: this is a groove on the upper surface of the MHC class I molecule, which 
binds antigenic peptides of 8-10 amino acids in length51,54-56 that bear specific 
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anchor residues in position 2 and at the C-terminus (Figure 4). For these residues, 
that occupied the groove (designated B and F) in the antigen binding site of class I 
molecules57,58, it has been demonstrated that a polymorphic mutation influences 
the repertoire of peptides bound by a particular MHC type59,60. 
 
 
 
 
 
 
 
 
 
 
  Figure 4. MHC class I molecule structure. 
 
For the final peptide loading onto MHC, the first step in the trafficking process, 
after proteasome epitope generation, is the transport of peptides from the cytosol 
to the endoplasmic reticulum (ER) lumen. This is achieved by the transporter 
associated with antigen processing complex (TAPs) consisting of two multiple 
membrane-spanning subunits, TAP1 and TAP261. TAPs preferentially bind 
peptides of 8–16 residues with a hydrophobic or basic C-terminal residue. After 
peptide-binding, TAPs undergo a conformational change, which facilitates the 
ATP-dependent transport of peptides into the ER lumen. Newly synthesized MHC 
class I molecules can then non-covalently bind peptide constituting the peptide-
loading complex. After peptide-binding, folding of the MHC class I molecule is 
complete, allowing the complex to exit the ER, travel through the Golgi and reach 
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groove
Peptide
INTRODUCTION                                                                                                                        Part II                                                                                                                                      
 66 
the cell surface (Figure 5). There, the peptide/MHC complex is subject to 
surveillance by CD8+ T cells.  
 
Figure 5. The endogenous pathway of antigen presentation. In the virus-infected cell, viral protein 
translated in the cytosol are degradated by proteasomes into peptides containing antigenic 
determinants. The antigenic peptides are transferred into the ER by TAP proteins and loaded onto 
antigenic groove of newly synthesized MHC class I molecules. Then the peptide/MHC-I complex 
traverses the Golgi apparatus and is presented on the plasma membrane. Here the peptide/MHC-I 
complex may be recognized by the cognate T-cell antigen receptor of a CD8+ cytotoxic T 
lymphocyte. 
 
 
1.1.4 Viral and tumor escape mechanisms 
 
Presumably, because of the selective pressure exerted by the immune system, 
many viruses have evolved proteins that interfere with antigen presentation by 
major histocompatibility complex class I molecules. These viruses utilize a whole 
variety of ingenious strategies to inhibit the MHC class I pathway62. Viral proteins 
often exploit bottlenecks in the MHC class I pathway down-regulating TAP 
expression and as a consequence reducing the peptide translocation into ER63. 
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Alternatively, viral protein can cause the degradation or mislocalization of MHC I 
molecules62-64. This is often achieved by subversion of the host cell‟s own protein 
degradation and trafficking pathway. However MHC class I total loss is frequently 
associated also with mutations in the β2-microglobulin gene that result in loss of 
functional β2-microglobulin expression
65. Another strategy employed to evade the 
immune system surveillance is to interfere with the proteolysis processes, for 
example modifying proteasome or other peptidases activity in order to prevent 
antigenic peptides generation66,67. In particular all these listed mechanisms, 
evolved in immune escape, are often common both in viruses and in tumors. 
 
 
1.2 EPSTEIN BARR VIRUS 
 
Epstein Barr virus (EBV) is a member of the herpesvirus family. It belongs to 
gammaherpesvirus subfamily and is an enveloped virus that contains a DNA core 
surrounded by an icosahedral nucleocapsid and a tegument. Its double-stranded 
DNA genome is 184Kpb long and encodes for more than 85 genes. EBV is 
widespread in all human populations in fact infects >90% of the world‟s people. It 
is the etiological agent of infectious mononucleosis (IM) but often gives 
asymptomatic infection if contracted in childhood. Upon primary infection, the 
individual remains a lifelong carrier of the virus and EBV can be transmitted by 
salivary contact. During acute infection, EBV primarily infects and replicates in the 
stratified squamous epithelium of the oropharynx. This is followed by a latent 
infection of the B lymphocytes. EBV infection of B lymphocytes is thought to occur 
in the oropharyngeal lymphoid organs, and in normal carriers, the virus persists in 
circulating memory B cells in episomal form. The B-lymphotropic nature of EBV is 
evidenced by the ability of the virus to immortalize normal resting B lymphocytes in 
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vitro, converting them into permanently growing lymphoblastoid cell lines (LCL). 
They carries multiple extrachromosomal copies of the viral episome (Figure 6) and 
constitutively expresses a limited set of viral gene products, the so-called latent 
proteins, which comprise six EBV nuclear antigens (EBNA1-6, also called EBNA 1, 
2, 3A, 3B, 3C and -LP) and three latent membrane proteins (LMP 1, 2A and 2B)68.  
 EBV is one of the most widely studied herpesvirus member because of its clinical 
and oncogenic importance, in fact recently it has been implicated in the 
pathogenesis of an increasing number of human malignancies such as Burkitt‟s 
lymphoma, Hodgkin‟s disease and nasopharyngeal carcinoma . 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. EBV genome: latent genes. 
 
1.2.1 EBV infection 
 
There are two distinct stages of the EBV life cycle. In latent infection, the genome 
is maintained at a constant copy number and a limited number of regions of the 
genome are expressed. In the other stage of infection (lytic cycle), viral DNA is 
amplified and a variety of viral antigens (lytic antigens) are produced prior to virion 
maturation. 
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1.2.1.1 Latent infection 
 
The entry of EBV into B cells is initiated by an interaction between the major viral 
envelope glycoprotein gp350 and the B-lineage-associated C3d complement 
receptor CR2 (designated CD21). Infection of B lymphocytes with EBV results in 
persistent latent infection and immortalization of the cells to perpetual proliferation 
(Figure 7A). Specifically, EBV infection induces RNA and DNA synthesis, 
immunoglobulin (Ig) secretion, expression of B-cell activation markers, and cell 
division69. Most of the details of latent infection in B lymphocytes have been drawn 
from studying EBV gene expression in LCLs. These cells express at least 11 EBV 
genes: two small polyadenylated RNAs (EBER-1 and EBER-2), EBNA1 through 
EBNA6, and the integral membrane proteins LMP1, LMP2A, and LMP2B. The 
proliferation of EBV-infected cells, normally, is monitored in vivo by T lymphocytes 
that specifically recognize viral antigens as peptides derived from the processing 
of endogenously expressed viral proteins presented on the surface of the target 
cell as a complex with MHC class I molecules70. In particular, EBNA3, EBNA4 and 
EBNA6 contain immunodominant epitopes for CTL responses over a wide range 
of HLA backgrounds71,72. In contrast, EBNA2, EBNA5, LMP1 and LMP2 are 
subdominant targets that are presented in the context of a limited number of HLA 
restrictions72,73,74. 
 
1.2.1.2 Lytic infection  
 
In contrast to the latent phase of infection, when only a limited number of proteins 
are expressed, activation of the EBV lytic cycle is characterized by the appearance 
of as many as 80 virus-specific RNA species. On the basis of their time of 
appearance postinduction, these transcripts are designated early (immediate early 
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and delayed early) or late. Early genes are expressed independently of new 
protein synthesis, after switching the virus from latency into replication mediated 
by an early protein (BZLF1). Afterwards, for  a successful packaging of the viral 
DNA and virion formation, are translated the components of the EBV late-antigen 
complex, which are mostly structural viral proteins. These new generated virions 
will definitively induce other infective cycles. Although considerable information 
has been generated recently on T-cell responses to viral antigens expressed 
during the latent cycle, much less is known about the contribution of cellular 
immunity against antigens synthesized during the viral replication cycle. 
This is mainly because there is no known in vitro grown cell that can serve as the 
target for a fully permissive EBV infection. However it is well known that T cells 
play an important role in controlling the replicative EBV infection. In fact 
significantly increased shedding of virus has been found in the oropharynx of 
immunosuppressed or immunodeficient individuals.  
 
 
 
Figure 7. (A) In vitro EBV infection of a B lymphocyte and its transformation into permanently 
growing lymphoblastoid cell line (LCL). (B) EBV infection: latency and lytic phases are shown 
respectively.  
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1.2.2 EBNA1 protein 
 
EBNA1 is a sequence-specific DNA binding phosphoprotein that is required for the 
replication and maintenance of the EBV genome. It also has a central role in 
maintaining latent EBV infection. EBNA1 is a 641 amino acid protein with a large 
internal repeat of glycine-alanine (Gly-Ala repeat domain, GAr) which make up 
about one third of the entire protein, but varies in length with every viral strain. 
EBNA1 presents also a DNA-binding domain (DBD) that, together with the nuclear 
localization signal (NLS), enhance transfection of EBV plasmids by facilitating their 
nuclear transport (Figure 8). EBNA1, encoded by the BKRF1 open reading frame, 
is the only virus-encoded trans-acting factor required for initiation of latent viral 
DNA replication and episomal maintenance. It performs these functions binding 
the origin of plasmid replication (OriP) or interacting with the latent Q promotor 
(Qp) respectively. Although a subset of genes is responsible for the growth-
transforming function of EBV, EBNA1 is the only viral gene that is regularly 
detected in all EBV-associated tumors and is required for the long-term 
persistence of EBV as well as the pathogenesis of EBV-associated cancers. 
Although in the past this protein has been considered undetected by the cell-
mediated immune system, recent studies show that EBNA1 can be presented to 
both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy 
of EBV related cancers. 
 
 
 
 
 
 
                    Figure 8. EBNA1 protein structure. 
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In fact, conflicting with previous observations71,74,75, CTL responses against 
EBNA1 have been detected in healthy EBV-seropositive individuals76-80 but, thus 
far, the poor recognition and killing of target cells which naturally express EBNA1 
by EBNA1-specific CTL cultures suggest a poor presentation of EBNA1-derived 
CTL epitopes (Figure 9). This has been attributed to the presence of Gar domanin, 
which prevents the presentation of EBNA1-derived antigenic peptides by MHC 
class I molecules. Furthermore, this GAr-mediated function has been linked to its 
capacity to prevent EBNA1 synthesis81,82 and block proteasomal degradation83,84. 
Although the role of the GAr domain on the stability/turnover of EBNA1 has only 
partially been clarified, it is now evident that EBNA1 is immunogenic and capable 
of inducing CD8-mediated cells responses. As EBNA1 is the only antigen 
expressed in all EBV-associated tumors, and therefore represents an ideal 
tumour-rejection target for immunotherapy against EBV-associated malignancies, 
elucidation of the mechanisms by which EBNA1-specific CTLs recognize naturally 
EBNA1-expressing cells remains crucial85,86. 
 
 
Figure 9. Known EBNA-1 epitopes presented by MHC-I molecules. 
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1.3 EBV ASSOCIATED MALIGNANCIES 
 
EBV was the first virus to be identified as a cause of human cancers. Although it 
infects about 90% of the adult human population, it has been implicated as the 
causal agent of tumors only in a small percentage of EBV seropositive individuals. 
EBV-associated diseases include Burkitt's lymphoma, Hodgkin's lymphoma, 
nasopharyngeal carcinoma and immunoblastic lymphoma. All these EBV 
associated malignancies are characterized by a specific latency program which 
provides for the expression of specific viral antigens (Figure 10). EBNA1 is the 
only viral protein expressed in all tumors; this expression pattern is called latency 
I. Most other EBV-associated malignancies, like for example Hodgkin‟s lymphoma 
and nasopharyngeal carcinoma, express either the two latent membrane proteins 
LMP1 and LMP2 in addition to EBNA1; this is termed latency pattern II. Finally the 
expression of all EBV latent antigens, EBNA1 to 6, LMP1 and LMP2, common in 
lymphoproliferative disease, is the latency III expression pattern. 
 
 
Figure 10. EBV-associated malignancies and their specific latency program. 
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1.3.1 Burkitt’s lymphoma 
 
Burkitt‟s lymphoma (BL) is the most common childhood cancer in certain parts of 
equatorial Africa and Papua New Guinea. There are three recognized forms of this 
tumor: endemic, sporadic, and AIDS-associated BL. In spite of their clinical 
heterogeneity, all bear one of three reciprocal translocations between 
chromosome 8, near the site of the c-myc locus at 8q24, and either the Ig heavy-
chain locus on chromosome 14 (the common translocation seen in up to 80% of 
tumors) or one of the light-chain loci on chromosome 2 or 22 (the variant 
translocations). Endemic BL accounts for approximately half of all childhood 
lymphomas occurring in equatorial Africa and Papua New Guinea and has an 
unusually high incidence of 8 to 10 cases per 100,000 people per year. EBV is 
present in tumor cells of more than 90% in African BLs, in the regions where 
malaria is hyperendemic. The association of BL with EBV is based on two 
observations: the demonstration of EBV genome in the majority of tumors from 
areas where the disease is endemic and the finding that BL patients have an 
unusually high titer of antibodies against EBV about 5 years before the clinical 
appearance of tumors. Endemic BL shows the strongest and most consistent 
association with EBV although the exact role which the virus plays in the etiology 
and pathogenesis of the tumor is still controversial. The virus might have an 
initiating role in which growth-transforming B-cell infections establish a pool of 
target cells that are at risk of a subsequent c-myc  translocation, a process that 
has been successfully modelled in vitro87. Alternatively, EBV might contribute to 
the Burkitt‟s lymphoma phenotype through the latency I-active genes themselves. 
EBNA1 is an obvious candidate, but its reported oncogenicity in mouse transgene 
assays remains controversial88, and its contribution to virus-induced B-cell 
transformation in vitro seems to be limited to maintenance of the viral genome89. 
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1.3.2 Hodgkin's lymphoma and  nasopharyngeal carcinoma 
 
Hodgkin's lymphoma is an EBV positive tumor in 90% of cases. This disease 
affects the lymph nodes and can easily spread through the lymphatic system to 
various organs and tissues. Hodgkin's disease (HD) displays a latency II program 
where EBNA1, LMP1, LMP2A and LMP2B proteins are expressed. In HD there is 
a high expression of activation antigens and MHC II antigens. In patients with 
nasopharyngeal carcinoma (NPC) has been found a significant depression of 
EBV-specific CTL responses. Nasopharyngeal cancer affects the epithelial cells 
on the nasopharynx surface and can be classified in three types: squamous cell, 
non-keratinized, or undifferentiated. It is one of the most common cancers in 
southern China and occurs less commonly in North African Arabs. The high 
incidence of NPC among southern Chinese suggests that, other than EBV, genetic 
or environmental factors may also contribute to the development of this carcinoma. 
NPC belongs to a latency II program, with EBNA1 and LMP1 protein expression. 
Several studies have demonstrated that proteasome/TAP pathway involved in 
antigen presentation remains unaltered in tumor cells both in Hodgkin's lymphoma 
and in nasopharyngeal carcinoma. 
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2 MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 Cell lines 
 
Lymphoblastoid cell lines (LCL) were obtained by infection of lymphocytes from 
HLA-typed donors with culture supernatants of a B95.8 virus-producing cell line, 
cultured in the presence of 0,1 g/ml of cyclosporine A (Sandoz International 
GmbH, Holzkirchen, Germany). LCL and Burkitt cell lines (BJAB B95.8 and Jijoye) 
were maintained in RPMI-1640 supplemented with 2 mM glutamine, 100 IU/ml 
penicillin, 100 g/ml streptomycin and 10% heat-inactivated fetal calf serum 
(HyClone; Thermo Fisher Scientific Inc., Waltham, MA). The BJAB (B-cell 
lymphoma) E1 and E1ΔGA were kindly provided by Prof. MG Masucci  
(Department of Cell and Molecular Biology, Karolinska Institute, Stockholm); briefly 
were generated upon transfection using an amaxa V solution kit (Amaxa, Cologne, 
Germany) and were maintained in selection with 0,2 mg/ml G418 (Gibco; 
Invitrogen, San Diego, CA). PHA-activated blasts were obtained by stimulation of 
PBLs with 1 g/ml purified PHA (Wellcome Diagnostics, Dartford, England) for 3 
days, and expanded in medium supplemented with human rIL-2 (Proleukin, Chiron 
Corporation, Emeryville, CA, USA)72.  
 
2.1.2 Synthetic peptides 
 
Peptides were synthesized by solid-phase method and purified to >98% purity by 
HPLC91. Structural verification was performed by elemental and amino acid 
Part II                                                                                                    MATERIALS AND METHODS 
 
 77 
analysis and mass spectrometry. Peptide stocks were prepared in DMSO at 10-2M 
concentration and maintained at -20°C. 
 
2.2 METHODS 
 
 
2.2.1 Proteasomes purification  
 
Cell were washed in cold PBS and resuspended in buffer containing 50 mM TRIS-
HCl (pH 7.5), 5 mM MgCl2, 1 mM DTT (Sigma), 2 mM ATP and 250 mM sucrose. 
Glass beads equivalent to the volume of the cell suspension were added, and the 
mixture was vortexed for 1 min at 4°C. Beads and cell debris were removed by 5 
min centrifugation at 1,000g, followed by 20 min centrifugation at 10,000g. Lysates 
were cleared by ultracentrifugation for 1 hr at 100,000g, and supernatants were 
then ultracentrifuged for 5 hr at 100,000g66. Proteasome-containing pellets were 
resuspended in 0.5 ml of homogenization buffer [50 mM TRIS-HCl (pH 7.5), 100 
mM KCl, 15% glycerol]. Protein concentration was determined using the BCA 
protocol (Pierce, Rockford, IL). 
 
2.2.2 Enzymatic assays 
 
The chymotrypsin-like and trypsin-like activities of purified proteasomes were 
tested using the fluorogenic substrates Suc-LLVY-AMC and Boc-LRR-AMC, 
respectively66. Fluorescence was determined by a fluorimeter (Spectrafluor plus; 
Tecan, Salzburg, Austria). Proteasome activity is expressed as arbitrary units of 
fluorescence (A.U.F). 
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2.2.3 Peptide degradation 
 
In vitro degradation of HPVGEADYFEYHQEGG (HPV + 5) was performed using 
150 µg of the peptide and 150 µg of purified proteasomes in 450 µl of activity 
buffer at 37°C. At different time points, 80 µl of samples were collected, and the 
reaction was stopped by adding 2 vol of ethanol at 0°C. Digestion mixtures were 
centrifuged, and 80 µl of supernatant was collected and analyzed by HPLC90.  
 
2.2.4 Western blot assay 
 
Equal amounts of proteins or equal amounts of purified proteasomes were loaded 
onto a 12% SDS-PAGE and electroblotted onto Protran nitrocellulose membranes 
(Schleicher & Schuell Microscience, Keene, NH). Blots were probed with Abs 
specific for α, LMP2, LMP7, MECL1 subunits, PA28 α-β, 19S, TAP1 and TAP2, 
and developed by ECL (Amersham Biosciences, Uppsala, Sweden)90. 
 
2.2.5 Preparation of antigen-presenting cells 
 
T2 and T2/A24 cells (2·106) were cultured overnight at 26°C in 1 ml of serum-free 
AIM-V medium. Cells were then washed, treated with mitomycin C to avoid cell 
proliferation, and pulsed for 3 hr with 10-5M of the different peptides in AIM-V 
medium at 37°C. After extensive washing, the cells were used as stimulators. 
 
2.2.6 Generation of memory CTL cultures 
 
Monocyte-depleted PBLs from HLA B35-restricted EBV-seropositive subjects were 
plated in RPMI-1640 containing 10% fetal calf serum (HyClone), at 3·106 cells per 
well in 24-well plates, and stimulated with either EBV encoded nuclear antigen 1 
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(EBNA1)-derived HPVGEADYFEY (HPV, aa 407–417) or EBV-encoded nuclear 
antigen 3 (EBNA3)-derived YPLHEQHGM (YPL, aa 464–473) peptide. For HLA-
A2 EBV-seropositive subjects, PBLs were plated at the same above condition, but 
were stimulated with predicted peptide-pulsed T2 cells at a stimulator : responder 
ratio of 1 : 20. Cultures were restimulated after 7 and 14 days, and the medium 
was supplemented from day 8 with 10 U/ml rIL-2 (Chiron, Milan, Italy). On days 14 
and 21, T-cell cultures were tested for CTL activity by cytotoxicity assay.  
 
2.2.7 Cytotoxicity assay 
 
Cytotoxic activity was tested by a standard 5 hr 51Cr-release assay73. Briefly, 
target cells were labelled with 0,1 µCi ⁄ 106 cells of Na2
51CrO4 for 90 min at 37 °C 
and, where indicated, were pulsed for 45 min with 10-6M of the different peptides 
at 37°C. Cells were then washed, and 4 · 103 cells were used as targets of each 
CTL at different E:T ratios. The percent specific lysis was calculated as 
100x[(c.p.m. sample) – (c.p.m. medium)/(c.p.m. Triton X-100) – (c.p.m. medium)], 
where c.p.m. represents counts/min. Spontaneous release was always < 20% in 
all cases. None of the tested peptides affected spontaneous release. 
 
2.2.8    IFN-  ELISPOT 
 
Enzyme-linked immunosorbent spot-forming cell assay [ELISPOT; for interferon-  
(IFN- )] was carried out using commercially available kits (Becton-Dickinson, 
Franklin Lakes, NJ) according to the manufacturer‟s instructions. In brief, 96-well 
nitrocellulose plates were coated with 5 g/ml of anti-IFN- , and maintained at 4°C 
overnight. The following day the plates were washed four times with phosphate-
buffered saline and blocked for 2 hr with 10% fetal bovine serum-supplemented 
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RPMI-1640 at 37°C. CTLs were added to the wells (in triplicate) at a ratio of 10 : 1 
and incubated with target cells at 37°C for 24 hr. Controls were represented by 
cells incubated with PHA (Sigma-Aldrich, St Louis, MO; 5 g/ml) (positive control), 
or with the medium alone (negative control). Spots were read using an ELISPOT 
reader (A.EL.VIS GmbH, Hannover, Germany). Results are expressed as net 
number of spot-forming units (SFU)/106 cells. 
 
2.2.9    Immunofluorescence detection of HLA-ABC molecules 
 
Surface expression of HLA-ABC molecules was detected by indirect 
immunofluorescence using anti-human HLA-ABC mouse monoclonal antibody (BD 
Pharmingen, San Diego, CA, USA). Mean logarithmic fluorescence intensity was 
determined by a fluorescence-activated cell sorter (FACS) analysis (Bryte HS, Bio-
Rad, Milan, Italy). 
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3 AIMS 
 
Cytotoxic T lymphocytes play a key role in immune system responses to identify 
and eliminate virus-infected cells or tumors. In particular, CTLs recognize antigens 
generated from peptide degradation by proteolytic systems and presented through 
HLA class I molecules on cellular membrane.  
A characteristic of viruses is their ability to escape from immune control interfering 
for example with major processes of proteolysis by altering the activity of the 
proteasome and other peptidases involved in the generation of antigenic peptides. 
In this context is inserted the EBV latency protein EBNA1, whose several new 
epitopes have been recently identified, despite it was considered since long time a 
not immunogenic protein. EBNA1, being expressed in all EBV associated tumors, 
represents an optimal target for immune therapies aimed at enhancing the 
recognition of tumor cells by the immune system. The study of EBNA1-specific 
CTL responses and analysis of the processes involved in creating a specific 
epitope are therefore of considerable importance for the development of new 
therapeutic approaches against tumors associated with Epstein Barr virus. 
The main purposes of the second part of this thesis are: 
1) the identification of new epitope-specific T cell responses directed against 
EBNA1; 
2) the evaluation of EBNA1-specific cytotoxic responses against an EBNA1 
derived CTL epitope and its presentation in lymphoblastoid cell lines (LCL) and 
Burkitt‟s lymphoma cells (BL); 
3) the identification of specific treatments to modulate antigen processing and to 
increase tumor immunogenicity.  
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HLA Sequence Name EBNA1 aa
A2 FLQTHIFAEV FLQ 565-574
SIVCYFMVFL SIV 557-566
A24 VYGGSKTSL VYG 509-517
LYNLRRGTAL LYN 517-526
4 RESULTS 
 
4.1 IMMUNE RECOGNITION AND EBNA1 DERIVED EPITOPE 
PRESENTATION IN LCL AND BL CELLS  
 
4.1.1 Identification of a new EBNA1 epitope 
 
To identify new CTL epitopes within the EBNA1 latent antigen, the amino acid 
sequence of the protein was analysed by a web-based algorithm that predicts 
peptide binding to HLA-A2, and HLA-A24 (http://www-bimas.cit.nih.gov/cgi-
bin/molbio/ken_parker_comboform). This analysis yielded a list of peptide 
sequences containing putative binding motifs and an estimation of the half-time 
dissociation of the HLA–peptide complex92. As the stability of MHC class I-peptide 
complexes is a crucial factor in determining CTL responsiveness73,93,94 only 
peptide sequences with the highest scores for HLA-A2 and HLA-A24 molecules, 
respectively, were selected for further analysis (Table 1). The PBLs obtained from 
healthy HLA class I-typed EBV-seropositive donors (20 donors: 14 HLA-A2, 10 
HLA-A24 and four HLA-A2, HLA-A24), were stimulated with peptides or peptide-
pulsed T2 or T2/A24 cells. The specificity of the CTL cultures was tested after 
three stimulations using standard 51Cr-release assays against autologous PHA-
blasts, pulsed or not with the relevant synthetic peptide.  
 
 
 
 
 
Table 1. Predicted Epstein Barr virus nuclear antigen 1 (EBNA1)-derived epitopes selected and 
tested in this study. 
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Only cultures that showed specific lysis (peptide pulsed target – unpulsed target) 
above 20% were considered as epitope-specific. Based on this criterion, the HLA-
A2-restricted 10-mer FLQ was deemed to induce peptide-specific responses in 
three of the 14 HLA-A2 donors tested (Figure 1A) while no specific responses 
were detected against other predicted EBNA1-derived epitopes SIV, LYN, VYG 
(data not shown). It is noteworthy that the frequency of FLQ responders (21%) 
was significantly lower compared with the frequency of responders to HLA-A2-
restricted epitopes derived from EBNA3 (SVR) and LMP2 (CLG and LLW), which 
ranged between 42% and 93% of the donors; leading to the hypothesis that this is 
a weak epitope. To identify the minimal epitope sequence presented by HLA-A2, 
polyclonal CTL cultures derived from the three responders (Figure 1A) were 
cloned by limiting dilutions and four CD8+ FLQ-specific CTL derived from donor 19 
were selected for further analysis. The PHA-blasts were pulsed with different 
concentrations of the FLQ peptide and used as a target of FLQ-specific CTL in 
cytotoxic assays. As shown in Figure 1B, half-maximal lysis was detected at high 
peptide concentrations (10-7M), suggesting that, despite possessing the correct 
anchor residues for binding HLA-A2 molecules, FLQ 10-mer peptide may not 
represent the minimal epitope sequence. Two shorter peptides were therefore 
synthesized and tested for their ability to sensitize autologous PHA-blasts. As 
shown in Figure 1B, the 9-mer peptide EBNA1 565–573 (LQTHIFAEV) was able to 
sensitize target cells at 10-10M concentrations, suggesting that it corresponds to 
the minimal epitope sequence. This was confirmed by the capacity of the LQT 9-
mer to stimulate memory T-cell responses (data not shown).  
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Donor HLA Type Donor HLA Type
1 A24, A32, B13, B35 11 A2, A24, B44, B39
2 A1, A24, B14, B35 12 A2, A28, B18, B75
3 A24, B35, B37, B35 13 A2, A24, B8, B60
4 A3, A24, B27, B35 14 A24, B7, B44
5 A2, B18, B35 15 A2, B44, B51
6 A24, B7, B35 16 A2, A36, B13
7 A2, A24, B35 16 A2, A26, B38, B57
8 A2, A10, B18, B35 18 A2, A24, B7, B18
9 A2, A11, B57, B35 19 A2, A26, B38, B63
10 A2, A26, B38, B39 20 A2, B18, B51
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Table 1. List of healthy EBV-seropositive donors exploited and their relative HLA type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) FLQ-specific cytotoxic T lymphocyte (CTL) cultures obtained from three donors. CTL 
cultures were obtained after three consecutive stimulations and were then tested against untreated 
or FLQ-pulsed autologous phytohaemagglutinin (PHA) -blasts. Results are expressed as the per 
cent specific lysis obtained at the indicated effector : target ratio. One representative experiment 
out of three is shown. (B) Peptide titration. FLQ-specific CTL clones were tested against 
autologous PHA-blasts after pre incubation with the indicated concentration of synthetic peptides 
from EBNA1 region 565–574. The minimal epitope was defined as the 9-mer LQTHIFAEV (EBNA1 
566–574). Results are expressed as the per cent specific lysis obtained at an effector : target ratio 
of 3 : 1. Means ± SD of three independent experiments performed in triplicate are reported. 
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4.1.2 Induction of EBNA1-specific memory CTL responses directed to the 
HLA-B35 and -B53-presented HPV CTL epitope 
 
It has been previously demonstrated that the HPVGEADYFEY (HPV) epitope, 
derived from the EBNA1 antigen (aa 407-417) and presented by HLA-B35 and B53 
alleles of the B5 cross-reactive group, is one of the target of EBNA1-specific CTL 
responses in healthy EBV-seropositive individuals95. 
In order to identify specific responses to this epitope and to obtain HPV-specific 
CTL cultures for further evaluation, we investigated the presence of HPV-specific 
memory CTL responses in a panel of HLA-B35 healthy EBV-seropositive 
individuals. To this end, PBLs obtained from 9 healthy HLA-B35 positive, EBV-
seropositive donors (Table 2) were stimulated with the HPV peptide73. As control, 
parallel stimulations were performed using the HLA-B35-presented YPL epitope 
derived from the EBNA3 antigen74. The specificity of CTL cultures was tested after 
three stimulations using standard 51Cr-release assays against autologous PHA-
blasts, pulsed or not with the relevant synthetic peptide. 
As shown in Figure 2, HPV-pulsed PHA-blasts were efficiently lysed by 
representative CTL cultures obtained from donors 5, 6, 7 and 8. Three of these 
donors also responded to the YPL epitope. Overall, these stimulations yielded 
HPV-specific CTL responses in 6 out of the 9 donors tested (Table 2). It should be 
noted that responses to the EBNA3-derived YPL epitope were detected in 4 out 8 
donors tested (Table 2). Thus, these results suggest that the EBNA1-derived HPV 
epitope would appear to be a relevant target of EBV-specific CTL responses.  
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Donor HLA Type
EBNA1 epitope 
HPVGEADYFEY
EBNA3 epitope 
YPLHEQHGM
1 A24, A32, B13, B35 - -
2 A1, A24, B14, B35 -   + 
3 A24, B35, B37, B35 + -
4 A3, A24, B27, B35 - -
5 A2, B18, B35 + +
6 A24, B7, B35 + -
7 A2, A24, B35 + +
8 A2, A10, B18, B35 + +
9 A2, A11, B57, B35 + nd
Specific CTL response 
Cytotoxic Activity
 (nd, not determined)  
Table 2. List of healthy HLA-B35 EBV-seropositive donors and their responses against HPV and 
YPL epitopes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. HPV-specific CTL cultures obtained from four different donors. As control, parallel 
stimulations were performed using the HLA-B35 presented YPL epitope derived from the EBNA3 
antigen. CTL cultures were obtained after three consecutive stimulations, and were then tested in 
triplicate against untreated, HPV or YPL-pulsed autologous PHA-blasts. Results are expressed as 
the percentage of specific lysis obtained at the indicated effector : target ratio. Mean ± SD of 3 
independent experiments is shown. 
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4.1.3 Recognition of LCL and BL by HPV-specific CTL cultures  
 
To investigate the presentation of the HPV CTL epitope in EBV-positive cells, 
HLA-B35 or -B53 positive LCLs and BLs were used as targets of HPV-specific 
CTL cultures obtained from donors 5 and 7. We found, in 5h 51Cr-release assay, 
that unmanipulated HLA-B35- and HLA-B53-matched LCLs were lysed by HPV-
specific CTL cultures (Figure 3A) while BLs were not recognized suggesting that 
the HPV epitope is poorly presented at the surface of BL cells (Figures 3B). To 
exclude poor sensitivity to lysis of BL lines, we evaluated the killing of BLs loaded 
with the synthetic HPV epitope by cytotoxic assay. We found that HPV-pulsed BL 
cells were recognized by HPV-specific CTLs indicating that BL cells are sensitive 
to lysis and able to present the HPV T-cell epitope when exogenously added 
(Figure 3B). IFN-  production assays have been mainly used in studies 
documenting the presentation of EBNA1-derived MHC-I-presented CTL epitopes 
since it is considered a more sensitive indicator of target cell recognition77,79-80. 
Therefore, we tested whether recognition of EBNA1-expressing BL cells could be 
revealed by monitoring IFN-  release in ELISPOT assays. To this end, HPV-
specific CTLs and matched LCLs and BLs were seeded at an effector : target ratio 
of 10:1, and the number of HPV-specific IFN-  producing cells was evaluated after 
24 hrs. As shown in Figure 3C, release of IFN-  was specifically induced by HLA-
B35-matched LCLs while HLA-B35- and -B53 matched BLs did not stimulate IFN-  
release, thereby confirming the poor presentation of this epitope in BL cell lines. 
As a whole, these results demonstrate that the EBNA1-derived HPV epitope is 
generated and presented in LCLs but not in BL cells.  
 
 
 
RESULTS                                                                                                                                   Part II 
 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Recognition of LCLs and BLs by HPV-specific CTL cultures. (A) HLA-B35 or -B53 
positive LCLs and (B) BLs were used in a 5h 
51
Cr-release assay as targets of HPV-specific CTL 
cultures obtained from donor 7. Target cells were tested either after HPV-pulse (+HPV) or no 
treatment (NT). Results are expressed as the percentage of specific lysis obtained at the indicated 
effector : target ratio. Mean ± SD of 3 independent experiments is shown. (C) Matched or 
mismatched LCLs and BLs were co-cultured for 24 hrs with HPV-specific CTL at an effector : target 
ratio of 10 : 1. Interferon-  (IFN- ) release was detected by ELISPOT. Results are expressed as net 
spot number/10
6
 cells. Mean ± SD of 3 independent experiments is shown. 
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4.2 DIFFERENCE IN ANTIGEN PROCESSING MACHINERY 
BETWEEN LCLs AND BLs 
 
 
4.2.1 Expression of  HLA class I and TAP molecules 
 
 Loss or down-regulation of HLA class I is one of the routes of immune escape in a 
variety of human tumors, including BL cell lines96-99. Therefore, the surface 
expression of class I molecules in BL lines (Jijoye and BJAB B95.8) and LCLs was 
tested by indirect immunofluorescence. As shown in Figure 4, Jijoye cells 
expressed lower amount of class I molecules while BJAB B95.8 cell lines showed 
similar levels of total HLA class I molecules, as compared to LCLs. However, 
significant levels of lysis were achieved by the addition of HPV peptide to BL cells, 
thereby suggesting that sufficient levels of class I molecules were expressed at the 
cell surface (Figure 3B). As the TAP1/TAP2 heterodimer is required for 
translocation of the majority of peptides from the cytosol into the lumen of the 
endoplasmic reticulum, lack of these proteins in the ER could also be a reason for 
limited presentation of MHC-I peptides99. In order to investigate this theory, TAP 
expression was evaluated by probing Western blots of total cell extracts with 
TAP1- and TAP2-specific antibodies, as shown in Figure 4. The obtained results 
demonstrate that Jijoye and BJAB B95.8 cells expressed both TAP proteins, albeit 
to a lesser degree than LCLs, thereby suggesting that lack of presentation of the 
HPV peptide antigen is not due to loss of TAP1/TAP2 expression. These results 
suggest that the expression of class I molecules and TAP, although very relevant 
in the presentation of MHC-I/peptide complexes, may only partially affect the 
presentation of the EBNA1-derived HPV epitope. Indeed, treatment of cells with 
IFN-  (Figure 8), which increases HLA class I molecules and TAP expression, 
does not sensitize target cells to lysis by HPV-specific CTLs. Furthermore, we 
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have demonstrated that BJAB cells are able to present the HPV epitope if they 
express a GAr-deleted form of EBNA1, suggesting that the lower expression of 
class I molecules and TAPs may only partially contribute to lack of the HPV 
epitope presentation78. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. HLA class I and TAP heterodimer expression in LCLs and BLs. In the upper panel, 
surface expression of HLA-I molecules as detected by indirect immunofluorescence is shown. 
Mean logarithmic fluorescence intensity was determined by fluorescence-activated cell sorter 
(FACS) analysis; thin and thick lines indicate the isotype control and the HLA-ABC signal 
respectively, for each cell line. In the lower panel, expression of TAP-1 and TAP-2 in two LCLs and 
in two BLs, as detected by Western blot analysis, is shown. β-Actin was used as loading control. 
One representative experiment out of three is shown. 
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4.2.2 Expression and activity of proteasomes in LCL and BL 
 
It has previously been demonstrated that BL cells express proteasomes with 
different subunit composition and enzymatic activity, perhaps resulting in the 
generation of a distinct set of MHC-I binding peptides66,100. 
Thus, we investigated the levels of expression of IFN- -regulated β subunits 
(LMP2, LMP7 and MECL-1) and proteasome regulators (PA28 α-β, 19S) in LCL 
and BL cells by Western blotting. As shown in a representative experiment (Figure 
5), Jijoye and BJAB B95.8 lines expressed levels of proteasomes comparable to 
those found in LCLs, evidenced by the detection of similar amounts of the 
constitutively expressed α subunits. However, a significant down-regulation of 
MECL-1 and a less marked down-regulation of LMP2 and LMP7 were detected in 
BL lines. To investigate whether these differences in the expression of subunit 
composition correlated with differences in enzymatic activity, we analyzed the 
chymotryptic- and tryptic-like activities of proteasomes semi-purified from LCL and 
BL cells in enzyme kinetics assays, using Suc-LLVY-AMC and Boc-LRR-AMC as 
reference substrates.  
Proteasomes isolated from BL cells demonstrated far lower chymotryptic-like and 
tryptic-like activities than proteasomes isolated from LCLs (Figure 6). This is in 
agreement with the pattern of expression of the catalytic subunits in LCLs, as 
increased expression of LMP7 and MECL1 is associated with increased 
chymotryptic and tryptic activities. 
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Figure 5. Expression of proteasome subunits and regulators in BL and LCL cells. Equal amounts 
of semipurified proteasomes were loaded onto a 12% SDS-PAGE and electroblotted onto Protran 
nitrocellulose membranes. The blots were probed with specific Abs, as reported in the Materials 
and Methods. β-Actin was used as loading control. One representative experiment out of three is 
shown. 
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Figure 6. Proteolytic activity of proteasomes isolated from BL and LCL cells. (A) The trypsin-like 
and (B) chymotrypsin-like activities of proteasomes are shown respectively. Proteasome activity is 
expressed as arbitrary units of fluorescence (A.U.F.). Mean ± SD of 3 independent experiments is 
shown. 
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4.3 MODULATION AND INDUCTION OF BLs RECOGNITION BY 
HPV-SPECIFIC CTL 
 
 
4.3.1 Evaluation of the effect of the Gly-Ala repeat domain on HPV-mediated 
lysis in BL 
 
The EBNA1 protein contains a GAr domain that inhibits proteasomal 
degradation84. Removal of GAr increases proteasome-dependent processing, 
leading to better presentation of EBNA1-derived CTL epitopes77,95. To assess 
whether the GAr was responsible for the poor presentation of the HPV epitope in 
BL cells, stable transfected sublines of BJAB that express either EBNA1 (BJAB 
E1) or a GAr-deleted EBNA1 (BJAB E1ΔGA) were used as target cells in a 
standard 51Cr-release assay. Interestingly BJAB E1ΔGA was efficiently recognized 
by HPV-specific CTL, confirming the inhibitory effect of the GAr domain on antigen 
processing in BL cells (Figure 7).  
 
 
 
 
 
 
 
Figure 7. Role of Gly-Ala domain (GAr) on HPV epitope presentation. HPV-specific cytotoxic T-
lymphocyte were tested against untreated or HPV-pulsed BJAB cells or BJAB cells stably 
expressing EBNA1 (BJAB E1) or the GAr-deleted form (BJAB E1ΔGA). Results are expressed as 
the per cent specific lysis obtained at the indicated effector : target ratio. One representative 
experiment out of three is shown. In the next panel, expression of EBNA1 (E1) and GAr-deleted 
EBNA1 (E1ΔGA) in transfected BJAB cells, as detected by Western blot analysis, is shown. 
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4.3.2 Modulation of antigen processing affects HPV epitope presentation in 
BL cells  
 
Previous results suggest that one of the major differences between BL cells and 
LCLs is in the expression and activity of proteasomes, which may result in poor 
generation of the HPV epitope. It has already been shown that modulation of 
antigen processing and partial inhibition of proteasomes may restore the 
generation of certain T cell epitopes101-103. Thus, we treated BL cells with 
molecules which modulate various steps of the antigen processing pathways. 
Specifically, Jijoye cells were treated overnight either with proteasome inhibitors 
(MG132, epoxomicin and PS-341), tripeptidyl peptidase II inhibitors (butabindide 
and AAF-CMK), a lysosomal acidification inhibitor (chloroquine), an autophagic 
process inducer (rapamycin) or IFN- , which increases proteasome and ERAP 
activities as well as HLA class I and TAP expression. All drugs were used at the 
selected concentrations which correspond to their known biological effect without 
effects on cell viability. As shown in Figure 8, only partial inhibition of proteasomes 
leads to an increased recognition of Jijoye cells by HPV-specific CTLs, while all 
other treatments failed to affect target cell lysis. 
 
 
 
 
 
 
 
 
Figure 8. Effect on HPV-epitope presentation in BLs by modulation of different steps of the antigen 
processing pathways. HPV-specific CTL cultures were tested against Jijoye cells treated overnight 
or not with the indicated molecules. Results are expressed as the percent specific lysis obtained at 
the indicated effector : target ratio. Mean ± SD of 3 independent experiments is shown. 
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Similar results were obtained with BJAB B95.8 cells, while -B53 and -B35 negative 
BL cells, used as a negative control in all assays, were unaffected by these 
treatments (not shown). These results suggest that proteasomes from BL cells, 
although less efficient in degrading reference substrates than proteasomes from 
LCLs, destroy the HPV epitope, which can, however, be generated and presented 
after partial inhibition of the proteasomes. 
 
4.3.3 In vitro generation of HPV epitope by proteasomes isolated from BLs  
 
To evaluate whether proteasomes from BL cells are able to generate the HPV 
epitope, we analyzed the in vitro degradation of an HPV peptide precursor 
featuring 5 amino acids at the C terminus (HPV + 5). Proteasomes were semi-
purified from Jijoye cells treated or not with epoxomicin under the same conditions 
inducing HPV-specific lysis. Subsequently, the in vitro HPV precursor degradation 
was evaluated at different time points by HPLC analysis. As shown in Figure 9, the 
HPV precursor was degraded in a time-dependent fashion. Proteasomes isolated 
from Jijoye cells and treated with epoxomicin were still capable of degrading the 
HPV precursor, albeit to lesser extent. Interestingly, the appearance of a single 
peptide was evident during the HPV + 5 degradation. As this peptide eluted from 
the HPLC column with the same retention time as the HPV peptide, it was 
identified as the HPV epitope, a hypothesis confirmed by mass spectroscopy (data 
not shown). The generation of the HPV epitope by proteasomes isolated from 
untreated Jijoye cells was maximal after 1 h and subsequently decreased in a 
time-dependent fashion suggesting a further degradation to products which were 
undetectable under our conditions. In contrast, proteasomes isolated from Jijoye 
cells treated with epoxomicin still generated the HPV epitope, which was not 
further degraded since its presence could be still detected after 48 h. These in 
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vitro findings suggest that BL cells treated with proteasomes inhibitors do not 
degrade the HPV epitope resulting in its presentation by class I molecules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. In vitro generation of the HPV epitope by proteasomes isolated from BL cells. (A) The 
HPV + 5 peptide (HPV precursor) was incubated with proteasomes purified from Jijoye previously 
treated with 0,01 M epoxomicin or untreated (NT). HPV precursor degradation was monitored at 
different time points, and its degradation was evaluated by HPLC analysis. Data are expressed as 
peak area of HPV precursor. (B) HPV generation at different time points relating to the degradation 
of HPV precursor in Jijoye cells treated with 0,01 M epoxomicin or untreated (NT). Data are 
expressed as peak area of HPV, as evaluated by HPLC analysis. One representative experiment 
out of three is shown. Mean ± SD of 3 independent experiments is shown. 
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5 DISCUSSION 
 
As a result of its ubiquitous expression in EBV-associated malignancies, EBNA1 
has long been considered an ideal target for immunotherapeutic approaches104. 
The first part of this study was aimed at exploring new potential epitopes 
presented by HLA-A2 and HLA-A24 molecules. An epitope prediction algorithm 
was used to identify four potential epitopes that were then tested for their 
capacity to reactivate T-cell responses in PBLs from healthy EBV-positive 
donors. The LQT peptide corresponding to amino acids 566–574 of EBNA1 
induced HLA-A2-restricted CTL responses in three out of 14 HLA-A2-positive 
donors tested. It should be noted that the minimal epitope was not the one 
predicted by the algorithm although the latter contains the correct anchor 
residues for binding to HLA-A2 molecules105. This is in line with the observation 
that some CTL epitopes do not contain conventional anchor residues and 
binding to the presenting allele is instead dependent on secondary anchors. The 
reactivation of LQT-specific CTL in only three out of 14 of the donors tested 
suggests that this epitope may only account for a minor component of the EBV-
specific CTL response, suggesting that it is a particularly weak epitope. 
Afterwards to assay the presentation, in its natural context, of a known EBNA1-
derived epitope (referred as HPV, an HLA-B35/B53 presented epitope), HPV-
specific CTL cultures, generated by peptide stimulation from EBV-seropositive 
healthy individuals, were used. These cultures were tested against LCL and EBV-
positive BL cells using either cytotoxicity or IFN-  release. In the case of EBNA1-
specific T cell responses, failure to lyse EBNA1-expressing target cells has 
frequently been observed,95,106 although low levels of lysis have been reported in 
some studies79,80. In contrast, specific recognition of EBNA1-derived epitopes has 
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in many cases been revealed by the induction of IFN-  release, which is 
considered a more sensitive method for detecting target cell recognition. By this 
approach, we confirmed that the presence of HPV-specific T cell responses is in 
the same range as that seen for the immunodominant HLA-B35-restricted YPL 
epitope derived from EBNA380,107. This finding, together with the identification of 
other EBNA1-derived epitopes restricted by several class I alleles76-80, further 
highlights the importance of EBNA1 as a target of EBV-positive malignancies, and 
makes evaluation of the recognition of EBV-infected cells and EBV-associated 
malignancies by EBNA1-specific CTLs crucial. 
Hence, we set out to demonstrate that LCLs are recognized and killed by HPV-
specific CTL cultures, indicating that the GAr domain affords the protein antigen 
only partial protection from CD8+ T cell recognition. Therefore our results support 
the idea that EBNA1-specific T cell responses are primed in vivo by a direct 
interaction between the CD8 T cell repertoire and naturally infected B cells in 
which endogenously expressed EBNA1 is targeted intracellularly by the 
proteasome, despite the presence of the GAr domain77,79,80. 
In contrast to what observed in LCL, we show that BL cells were not recognized by 
HPV-specific CTLs, thereby suggesting that the GAr domain affords the EBNA1 
antigen protection from CTL-mediated lysis in this type of cells. Since it has 
previously been demonstrated that the stability of EBNA1 although varying in 
different cell lines, does not correspond to the level of generation of EBNA1-
derived CTL epitopes79, lack of presentation of the HPV epitope in BL cells should 
not be due to a GAr stabilization effect of EBNA1. Instead, it should be ascribable 
to the particular antigen processing machinery present in BL cells, which differs 
from that found in LCLs. Furthermore, deletion of the GAr domain has also been 
demonstrated to provoke no major effect on EBNA1 protection from degradation, 
suggesting that the GAr domain has other, as yet unidentified, effects108. 
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One of the major differences between BL cells and LCL is the proteasome66,98-99. 
Indeed, using the same cells assayed in cytotoxicity, BL cells were found to 
present proteasomes with a different subunit composition, correlating with a much 
lower chymotryptic and tryptic-like activities with respect to LCLs. This may result 
in their poor capacity to generate the HPV epitope due the presence of the GAr 
domain, whose deletion restores the capacity of BL cells to present the HPV 
epitope78. Indeed, we demonstrated that BJAB cells expressing a GAr-deleted 
EBNA1, are recognized by HPV-specific CTLs further confirming that low 
expression of HLA class I molecules and TAPs may only partially affect the 
presentation of the HPV epitope which is not generated and presented in BJAB 
expressing wild-type EBNA178. Intriguingly, we found that BLs treatment with 
proteasome inhibitors partially restores the capacity of BL cells to present the 
EBNA1 epitope, thereby suggesting that proteasomes from BL cells, although less 
active against prototype substrate peptides, which only partially indicate the in vivo 
proteasomal activities, degrade the HPV epitope during the processing of EBNA1. 
It remains to be elucidated whether other EBNA1-derived CTL epitopes may be 
more efficiently generated and presented after partial inhibition of proteasomes or 
whether this effect is restricted to the HPV epitope. Therefore, the question is 
whether the GAr domain can specifically alter EBNA1 processing by the 
proteasome in BL cells. Interestingly, it has been demonstrated that the effect of 
the GAr domain may either prevent or promote proteasomal degradation, 
depending on its location in the protein108. It is tempting to speculate that this 
effect may also be influenced by the type of proteasome, since it has been also 
shown that GAr affects the unfolding/recognition of protein substrates by 
proteasomes108. Although the role of GAr on the generation of EBNA1-derived 
CTL epitopes still remains to be elucidated and requires further investigation, in 
our experimental setting, it is clear that this domain affects the generation of the 
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HPV epitope in BL cells but not in LCLs demonstrating that GAr effects are cell-
dependent. 
In conclusion, our study together with previous reports strongly support the idea 
that EBNA1-specific CTLs might be exploited therapeutically to target EBV+ 
malignancies in combination with chemotherapy and/or protocols designed to 
restore antigen-presenting capacity in the tumor. In this context, it has been 
recently demonstrated that tubacin, a molecule which inhibits histone deacetylase 
6, demonstrates a fairly selective capacity to induce apoptosis in BL cells, but not 
in LCLs109. Furthermore, the combination of tubacin with a proteasome inhibitor 
induced efficient killing of BL cells109, which are known to be resistant to 
proteasome inhibitor-induced apoptosis66,110. These findings, together with those 
reported in this study, suggest that the use of proteasome inhibitors, alone or in 
combination with other drugs such as tubacin, may represent a strategy for the 
treatment of EBNA1 carrying tumors, since proteasome inhibitors, in addition to 
their effect as pro-apoptotic drugs may also increase the immunogenicity of 
EBNA1, thereby resulting in the efficient elimination of EBNA1-positive 
malignancies. 
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Abs Antibodies 
Al Aluminium 
APC Antigen Presenting Cell 
AraC Arabinoside C  
ATP Adenosine Triphosfate 
AUF Arbitrary Units of Fluorescence 
Au over Ni Gold over Nickel 
Au over Ni + ODT Gold over Nickel + Octadecanethiol 
Au over Pd Gold over Palladium 
Au over Pd + ODT  Gold over Palladium + Octadecanethiol 
2m 2-microglobulin
BLs Burkitt‟s lymphoma  
BOT Bottom 
Certonal FC-732T Certonal FC-732 tempered 
COCHISE Cell-On-CHIp bioSEnsor 
Cpm  Counts per minute 
CTL Cytotoxic T Lymphocytes 
Cu Copper 
Cu + ODT Copper + Octadecanethiol 
DAF Die attach film 
DEP Dielectrophoresis 
DEPC Diethylpyrocarbonate 
DI water  Deionized water 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
E:T Effector:Target 
E1 EBNA1 
EAs Early antigens  
EBNA EBV nuclear antigen  
EBV  Epstein Barr Virus 
ER Endogenous Reticulum 
ERAP Endoplasmic-reticulum aminopeptidase 
FBS Fetal bovine serum 
GAr Glycine-Alanine repeat domain  
HD Hodgkin disease 
HLA Human Leucocite Antigen 
HPLC High-performance liquid chromatography 
IFN Interferon 
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Ig Immunoglobulin 
IM Infectious Mononucleosis 
kDa Kilo Dalton 
KHz  Chilohertz 
LCL Lymphoblastoid cell line 
LMP1 and 2 Latent Membrain Protein 1 and 2 
LMP2 and 7 Low molecular weight protein 2 and 7 
LOC Lab-on-a-Chip 
LOC K562 K562 manipulated in Lab-on-a-chip  
MECL1 Multicatalytic endopeptidase like 1  
MEMS Microelectromechanical systems devices  
MHC Major Histocompatibility Complex 
MHz Megahertz 
µTAS Micro Total Analysis Systems 
MID Middle 
NK Natural Killer 
NPC Nasopharyngeal Carcinoma NPC 
ODT Octadecanethiol 
PA28 Proteasome Activator 28 
PBL Peripheral Blood Lymphocyte 
PCB Printed Circuit Board 
Pd Palladium 
Pd + ODT Palladium + Octadecanethiol 
PDMS Poly(dimethylsiloxane)  
PF after lam Polyurethane foil after lamination 
PF before lam Polyurethane foil before lamination 
PHA Phytohaemagglutinin  
PI Polyimide 
PP Polyurethane powder 
Py  Pyralux  
RCC Resin Coated Copper 
SAMs  Self-assembled Monolayers 
SD Standard Deviation 
SDS Sodium Dodecyl Sulfate 
SFU Spot-Forming Units  
TAP  Transporter associated with antigen processing 
TPPII Tripetidil peptidase II 
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